



NAME: MIGUEL VIVEIROS BETTENCOURT
DATE OF BIRTH: 18th October 1966
NATIONALITY: Portuguese
ADDRESS: Unit of Medical Microbiology
Global Health and Tropical Medicine
Instituto de Higiene e Medicina Tropical
Universidade NOVA de Lisboa
Rua da Junqueira, 100
P-1349-008 LISBOA
PORTUGAL
Tel.: (21) 365 26 53
Fax: (21) 363 21 05
E-mail: mviveiros@ihmt.unl.pt



ACADEMIC QUALIFICATIONS:

- 1991 Degree in Biology from Faculdade de Ciências da Universidade de Lisboa (FC/UL)
- 1995 Master of Science in Biotechnology (Biochemical Engineering) from Instituto Superior Técnico da Universidade Técnica de Lisboa (IST/UTL)
- 2001 PhD in Biology (Microbial Genetics) from Faculdade de Ciências da Universidade de Lisboa
- 2012 Habilitation in Biomedical Sciences (Speciality Microbiology) - (Agregação em Ciências Biomédicas – Especialidade Microbiologia) from Instituto de Higiene e Medicina Tropical/ Universidade Nova de Lisboa.

APPOINTMENTS AND WORKING ACHIEVEMENTS:

Oct/1991 - Sep/1992 - Research training in Virology; Supervision: Prof^a Wanda Canas-Ferreira; Laboratory: Departamento de Microbiologia do Instituto de Higiene e Medicina Tropical da Universidade Nova de Lisboa (IHMT/UNL); Subject: "Cell culture for HIV-2 isolation from Guinea-Bissau"
Lecturing Post-Graduation Course in Tropical Medical Microbiology.

Oct/1992 - Apr/1995 - Master of Science Course in Biotechnology (Biochemical Engineering) from IST/UTL and research activity in Molecular Genetics/Biotechnology with a Scholarship from Junta Nacional de Investigação Científica e Tecnológica (J.N.I.C.T./F.C.T.); Supervision: Prof^a Doutora Isabel Sá-Correia (IST/UTL) and Prof Dr. Hugo Ayres David (Institut Pasteur Paris); Laboratory: Microbiologia IHMT/UNL; Thesis: "Carotenogenesis in *Mycobacterium vaccae* - Genetic and biochemical characterization"

Apr/1995 – Mar/2001 - PhD Scholarship from J.N.I.C.T./F.C.T.; Supervision: Prof Dr. Hugo Ayres David (Institut Pasteur Paris and IHMT/UNL) and Prof. Dr. Filomena Exposto (IHMT/UNL); Laboratory: Microbiologia of IHMT/UNL.; Thesis: "Isolation of the carotenogenesis operon in *Mycobacterium vaccae*. - Application to the development of new mycobacterial genetic tools and to the understanding of molecular mechanism of tuberculosis pathogeny"

Jan/1998 – Mar/2001 - Lecturer (Assistente) in Medical Microbiology/Bacteriology in the Unit of Mycobacteriology of the IHMT/UNL. Lecturing activities in the Post-Graduation Course in Tropical Medical Microbiology and in the Faculty of Medical Sciences (Universidade Nova de Lisboa) – Microbiology and Parasitology -Third year of the Medical Degree Course. Research activities in Molecular Genetics of Mycobacteria, mycobacteria diagnosis and drug resistance.

Mar/2001 – Dec2009 - Assistant Professor (Professor Auxiliar) in Medical Microbiology/Bacteriology in the Unit of Mycobacteriology of the IHMT/UNL. Lecturing activities in the Masters Course (MSc) in Medical Microbiology from the IHMT/UNL; MSc Coordinator since 2003. Deputy Director of the Tuberculosis and Mycobacteria Clinical Laboratory. Research activities in Molecular Genetics of Mycobacteria and Bacteria, mycobacteria diagnosis, drug resistance and development of new drugs.

Dec2009 - April 2012 – Associate Professor (Professor Associado) in Medical Microbiology/Bacteriology in the Unit of Medical Microbiology (Group of Mycobacteriology) of the IHMT/UNL

Dec2009 – to date – Director of the Tuberculosis and Mycobacteria Clinical Laboratory. Services – Isolation, identification and drug susceptibility testing provided to the National System to Health and community. Applied research activities in Molecular Genetics of Mycobacteria and Bacteria, mycobacteria diagnosis, drug resistance and development of new drugs.

April 2012 to July 2013 - Associate Professor with Habilitation in Biomedical Sciences (Speciality Microbiology) (Professor Associado com Agregação em Ciências Biomédicas – Especialidade Microbiologia) in the Unit of Medical Microbiology (Group of Mycobacteriology) of the IHMT/UNL. Thesis: “As novas tecnologias de biologia molecular no diagnóstico precoce da tuberculose resistente: a sua integração e monitorização no contexto dos programas de controlo da tuberculose - The new molecular biology technologies in the early diagnosis of drug-resistant tuberculosis: its integration and monitoring in the context of TB control programs”.

July 2013 to date - Full Professor in Medical Microbiology (Professor Catedrático em Microbiologia Médica) in the Unit of Medical Microbiology (Group of Mycobacteriology) of the IHMT/UNL.

January 2010 to December 2020 – President of the Pedagogical Council of the IHMT/UNL.

October 2014 – October 2017 – Special Visiting Professor at Faculdade de Medicina da Universidade do Rio de Janeiro (Brasil). Ref _ CAPES218488

Teaching Activity (coordination and/or teaching):

Mestrado (2º Ciclo) em Microbiologia Médica da Universidade Nova de Lisboa (UNL) – MSc in Medical Microbiology of UNL. Curricular Unit of Medical Bacteriology and Curricular Unit of Tuberculosis and other Mycobacteriosis;

Mestrado (2º Ciclo) em Ciências Biomédicas (IHMT/UNL) – MSc in Biomedical Sciences of IHMT/UNL. Curricular Unit of Medical Microbiology;

Mestrado (2º Ciclo) em Saúde Tropical (IHMT/UNL) – MSc in Tropical Health. Lectures on Laboratory Diagnosis of Tuberculosis and Curricular Unit of Tuberculosis and other Mycobacteriosis;

Mestrado (2º Ciclo) em Saúde e Desenvolvimento (IHMT/UNL) – MSc in Health and Development. Lectures on Design of TB-Control programs;

Doutoramento (3º Ciclo) em Ciências Biomédicas (IHMT/UNL). PhD in Biomedical Sciences - Curricular Unit of Medical Microbiology and Curricular Unit of Tuberculosis and other Mycobacteriosis;

Doutoramento (3º Ciclo) em Genética Humana e Doenças Infeciosas (IHMT/UNL) – PhD in Human Genetics and Infection. Curricular Unit of Medical Microbiology and Mycology.

Supervised and/or co-supervised several postgraduate degrees - 5 pos-docs, 9 PhD, 30 MSc students.

Area of scientific activity: Scientific activity devoted to the early diagnosis of active or latent tuberculosis (TB) infections as well as the development of new therapeutical approaches to deal with MDRTB and with other drug resistant bacterial infections. Also interested in molecular biology of mycobacteria and immunology of TB. Executive Coordinator of the Masters in Medical Microbiology of the UNL. As Deputy-Director of the TB Laboratory of the IHMT (since 2001) has contributed to the resolution of the pulmonary TB problem of Lisbon by the generation of complete reports within a period of 15 to 20 days for 10 Hospitals of the TB Task Force of Lisbon. Over 180 studies published in peer review national and international journals in mycobacteriology, bacteriology, and resistance to antibiotics, microbial genetics, molecular epidemiology and immunology.

Domain of specializations: Medical Microbiology, bacteriology, mycobacteriology, laboratory diagnosis of mycobacterial infections, molecular biology and genetics of *Mycobacterium* sp. Tuberculosis. Molecular typing of multidrug-resistant *Mycobacterium tuberculosis*. Mechanisms and strategies to circumvent drug resistance in mycobacteria, composition of the mycobacterial cell wall/envelope in relation to drug resistance, new antibiotics, antibiotic uptake, efflux-pumps, drug targeting and molecular vectorisation, nanotechnology, flow-cytometry.

Present research interests: Research in tuberculosis and antibiotic resistant infections in support for alternative therapies of incurable diseases such as multidrug resistant tuberculosis and methicillin-vancomycin resistant staphylococcal infections. Immunology of tuberculosis. Strong interests in assisting Portuguese speaking countries of Africa in combating tuberculosis. Expertise in the laboratory diagnosis of tuberculosis infections.

Research funding: Principal Investigator/Team Leader of 15 research projects, nine completed, six on-going (aprox. 2,5M€ of funding) and team member (researcher) of other 20 research projects. Funding agencies: Fundação para a Ciência e a Tecnologia, Ministério do Ensino Superior e Ciência, Fundação Calouste Gulbenkian, Ministério da Saúde, Conselho de Reitores das Universidades Portuguesas (Portugal), European Union, National Institute of Health (NIH/USA).

Refereeing and Academic Societies activities: Consultant for the Portuguese National Directorate of Health, CPLP board and Health Ministries, Foundation of Sciences and Technologies of Portugal and ECDC.

Member of the EUCAST -AMST – Antimicrobial susceptibility testing of Mycobacteria working group.

https://eucast.org/ast_of_mycobacteria/

Member of the evaluation panel of Individual Doctoral and Post-doctoral Grant proposals - area Biomedical Sciences and Basic Medicine - Fundação para a Ciência e a Tecnologia – Ministério da Educação e Ciência de Portugal. Expert Evaluator for the Medical Research Council of UK calls (area Tuberculosis). Member of the Review and Advisory Panel of the Wellcome Trust Awards, UK. Ad-hoc reviewer for the expert panel of the The Research Foundation – Flanders (FWO), Belgium, Haut Conseil de l'Évaluation de la Recherche et de l'Enseignement Supérieur (HCERES), France and National Agency for Scientific Evaluation (ANEP), Spain. Member of the evaluation panels for the QREN R&D investment proposals of the Ministério da Economia de Portugal. Regular ad-hoc reviewer of several international scientific journal (Lancet, Nature, JAC, AAC, PlosOne, IJAA, Tuberculosis, BMC Microbiology, etc) . 2005 - present.

<https://publons.com/author/772597/miguel-viveiros#profile>

Academic and Science Management activities:

2005 – 2019 - Elected member and Vice-President of the General Council of the IHMT/UNL.

2009 - present - Elected member of the Scientific Council of the IHMT/UNL.

2009 – present – Director of the Tuberculosis and Mycobacteria Clinical Laboratory

2010 – 2019 - President of the Pedagogical Council of the IHMT/UNL.

2019 – present - SubDirector of the IHMT/UNL

2006 - 2014 – Member of the Directive Committee of the Portuguese Board of Biologists (Ordem dos Biólogos). Presently Secretary and Counselour for Health of the National Council.

<http://ordembilogos.pt/>

2017- 2021 – Member of the National Council for Health (Conselho Nacional de Saúde) by nomination from the Portuguese Board of Biologists

<http://www.cns.min-saude.pt/>

2010 - present - Founding member and Treasurer (until 2017), currently management committee member of the Study Group for Mycobacterial Infections (ESGMYC) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).

<https://www.escmid.org/index.php?id=897>

2017 – present – Vice-president of the Portuguese Society of Microbiology (Sociedade Portuguesa de Microbiologia)

<https://spmicrobiologia.wordpress.com/>

2017 - Elected Vice-Chair of the Gordon Research Conference - Multi-Drug Efflux Systems

<https://www.grc.org/multi-drug-efflux-systems-conference/2017/>

2019 - Elected Chair of the Gordon Research Conference - Multi-Drug Efflux Systems

<https://www.grc.org/multi-drug-efflux-systems-conference/2019/>

BIBLIOMETRICS:

Web of Science/Publons analysis: Total Articles in Publication List: 3; Sum of the Times Cited: 6;

h-index: 45

ResearcherID: A-7326-2008

URL: <https://publons.com/researcher/772597/miguel-viveiros>

Scopus analysis:

Total Articles in Publication List: 221

Sum of the Times Cited: 7683

h-index: 49

Scopus Affiliation: 7003949212

URL : <http://www.scopus.com/authid/detail.url?authorId=7003949212>

Google Scholar analysis:

Total citations:11706

h-index: 61

URL: <http://scholar.google.pt/citations?user=o39byr4AAAAJ&hl=en>

ORCID ID:

URL: <http://orcid.org/0000-0001-9676-6251>

Publons ID :

URL: <https://publons.com/author/772597/miguel-viveiros#profile>

Authenticus:

URL: <https://www.authenticus.pt/pt/profileOfResearchers/publicationsList/13666>

NOVAPure:

URL: <https://novaresearch.unl.pt/en/persons/miguel-viveiros-bettencourt>

CIÊNCIAVITAE

URL: <https://www.cienciavitae.pt/DF17-B4BF-8756>

PUBLICATIONS IN INTERNATIONAL PEER-REVIEW JOURNALS (N = 212):

1. Marquês JT, Frazão De Faria C, Reis M, Machado D, Santos S, Santos MDS, **Viveiros M**, Martins F, De Almeida RFM. In vitro Evaluation of Isoniazid Derivatives as Potential Agents Against Drug-Resistant Tuberculosis. *Front Pharmacol*. 2022 May 4;13:868545. doi: 10.3389/fphar.2022.868545.
<https://www.frontiersin.org/articles/10.3389/fphar.2022.868545/full>
2. Rodrigues L, Bento Cunha R, Vassilevskaia T, **Viveiros M**, Cunha C. Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates. *Molecules*. 2022 Apr 23;27(9):2723. doi: 10.3390/molecules27092723. PMID: 35566073; PMCID: PMC9099573.
<https://www.mdpi.com/1420-3049/27/9/2723>
3. Kritski AL, **Viveiros M**, Carvalho ACC. Rapid molecular diagnostics to detect resistance to second-line anti-TB drugs. *Int J Tuberc Lung Dis*. 2022 May 1;26(5):385-387. doi: 10.5588/ijtld.22.0121. PMID: 35505483.
<https://www.ingentaconnect.com/content/iatld/ijtld/2022/00000026/00000005/art00002;jsessionid=9huhig8pu90la.x-ic-live-01>
4. Antimycobacterial Susceptibility Testing Group. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. *Eur Respir J*. 2022 Apr 14;59(4):2200166. doi: 10.1183/13993003.00166-2022.
<https://erj.ersjournals.com/content/59/4/2200166.long>
5. Bateson A, Ortiz Canseco J, McHugh TD, Witney AA, Feuerriegel S, Merker M, Kohl TA, Utpatel C, Niemann S, Andres S, Kranzer K, Maurer FP, Ghodousi A, Borroni E, Cirillo DM, Wijkander M, Toro JC, Groenheit R, Werngren J, Machado D, **Viveiros M**, Warren RM, Sirgel F, Dippenaar A, Köser CU, Sun E, Timm J. Ancient and recent differences in the intrinsic susceptibility of *Mycobacterium tuberculosis* complex to pretomanid. *J Antimicrob Chemother*. 2022 Mar 9;dkac070. doi: 10.1093/jac/dkac070.
<https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkac070/6544883?login=true>
6. Rocha DMGC, **Viveiros M**, Saraiva M, Osório NS. The Neglected Contribution of Streptomycin to the Tuberculosis Drug Resistance Problem. *Genes (Basel)*. 2021 Dec 17;12(12):2003. doi: 10.3390/genes12122003.
<https://www.mdpi.com/2073-4425/12/12/2003>
7. Ortiz M, Jauset-Rubio M, Skouridou V, Machado D, **Viveiros M**, Clark TG, Simonova A, Kodr D, Hocek M, O'Sullivan CK. Electrochemical Detection of Single-Nucleotide Polymorphism Associated with Rifampicin Resistance in *Mycobacterium tuberculosis* Using Solid-Phase Primer Elongation with Ferrocene-Linked Redox-Labeled Nucleotides. *ACS Sens*. 2021 Dec 24;6(12):4398-4407. doi: 10.1021/acssensors.1c01710.
<https://pubs.acs.org/doi/10.1021/acssensors.1c01710>
8. Opota O, Mazza-Stalder J, **Viveiros M**, Cambau E, Santin M, Goletti D. Editorial: Tuberculosis and Non-tuberculous Mycobacteria Infections: Control, Diagnosis and Treatment. *Front Public Health*. 2021 Oct 28;9:666187. doi: 10.3389/fpubh.2021.666187.
<https://www.frontiersin.org/articles/10.3389/fpubh.2021.666187/full>
9. de Faria CF, Moreira T, Lopes P, Costa H, Krewall JR, Barton CM, Santos S, Goodwin D, Machado D, **Viveiros M**, Machuqueiro M, Martins F. Designing new antitubercular isoniazid derivatives with improved reactivity and membrane trafficking abilities. *Biomed Pharmacother*. 2021 Dec;144:112362. doi: 10.1016/j.biopha.2021.112362.
<https://www.sciencedirect.com/science/article/pii/S0753333222101146X?via%3Dihub>

10. de Lourdes do Carmo Guimarães Diniz J, von Groll A, Unis G, Dalla-Costa ER, Rosa Rossetti ML, Vianna JS, Ramos DF, Reis AJ, Bartolomeu Halicki PC, Rheingantz Scaini JL, Castillos de Ibrahim das Neves Y, Phelan J, Gomes AR, Campino S, Machado KDS, Werhli AV, Pain A, Clark TG, Perdigão J, **Viveiros M**, Portugal I, Almeida Silva PE. Whole-genome sequencing as a tool for studying the microevolution of drug-resistant serial *Mycobacterium tuberculosis* isolates. *Tuberculosis (Edinb)*. 2021 Dec;131:102137. doi: 10.1016/j.tube.2021.102137. <https://www.sciencedirect.com/science/article/pii/S1472979221000871?via%3Dihub>
11. Gómez-González PJ, Perdigão J, Gomes P, Puyen ZM, Santos-Lazaro D, Napier G, Hibberd ML, **Viveiros M**, Portugal I, Campino S, Phelan JE, Clark TG. Genetic diversity of candidate loci linked to *Mycobacterium tuberculosis* resistance to bedaquiline, delamanid and pretomanid. *Sci Rep*. 2021 Sep 30;11(1):19431. doi: 10.1038/s41598-021-98862-4. <https://www.nature.com/articles/s41598-021-98862-4>
12. Salvato RS, Reis AJ, Schiefelbein SH, Gómez MAA, Salvato SS, da Silva LV, Costa ERD, Unis G, Dias CF, **Viveiros M**, Portugal I, von Groll A, da Silva PEA, Kritski AL, Perdigão J, Rossetti MLR. Genomic-based surveillance reveals high ongoing transmission of multi-drug-resistant *Mycobacterium tuberculosis* in Southern Brazil. *Int J Antimicrob Agents*. 2021 Oct;58(4):106401. doi: 10.1016/j.ijantimicag.2021.106401. <https://www.sciencedirect.com/science/article/pii/S0924857921001667?via%3Dihub>
13. Rodrigues L, Aínsa JA, **Viveiros M**. Measuring Efflux and Permeability in Mycobacteria. *Methods Mol Biol*. 2021;2314:231-245. doi: 10.1007/978-1-0716-1460-0_9. https://link.springer.com/protocol/10.1007/978-1-0716-1460-0_9
14. Schön T, Werngren J, Machado D, Borroni E, Wijkander M, Lina G, Mouton J, Matuschek E, Kahlmeter G, Giske C, Santin M, Cirillo DM, **Viveiros M**, Cambau E. Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on *Mycobacterium tuberculosis*. *Clin Microbiol Infect*. 2021 Feb;27(2):288.e1-288.e4. doi: 10.1016/j.cmi.2020.10.019. <https://www.sciencedirect.com/science/article/pii/S1198743X20306509?via%3Dihub>
15. Tozar T, Santos Costa S, Udrea AM, Nastasa V, Couto I, **Viveiros M**, Pascu ML, Romanitan MO. Anti-staphylococcal activity and mode of action of thioridazine photoproducts. *Sci Rep*. 2020 Oct 22;10(1):18043. doi: 10.1038/s41598-020-74752-z. <https://www.nature.com/articles/s41598-020-74752-z>
16. Méchaï F, Cordel H, Guglielmetti L, Aubry A, Jankovic M, **Viveiros M**, Santin M, Goletti D, Cambau E. Management of Tuberculosis: Are the Practices Homogeneous in High-Income Countries? *Front Public Health*. 2020 Sep 4;8:443. doi: 10.3389/fpubh.2020.00443. <https://www.frontiersin.org/articles/10.3389/fpubh.2020.00443/full>
17. Tavares AM, Pingarilho M, Batista J, **Viveiros M**, Dias S, Toscano C, Gomes P, Abecasis AB. Short Communication: HIV and Tuberculosis Co-Infection Among Migrants in Portugal: A Brief Study on Their Sociodemographic, Clinical, and Genomic Characteristics. *AIDS Res Hum Retroviruses*. 2021 Jan;37(1):34-37. doi: 10.1089/AID.2020.0119. <https://www.liebertpub.com/doi/pdf/10.1089/aid.2020.0119>
18. Schön T, Köser CU, Werngren J, **Viveiros M**, Georghiou S, Kahlmeter G, Giske C, Maurer F, Lina G, Turnidge J, van Ingen J, Jankovic M, Goletti D, Cirillo DM, Santin M, Cambau E; ESGMYC. What is the role of the EUCAST reference method for MIC testing of the *Mycobacterium tuberculosis* complex? *Clin Microbiol Infect*. 2020 Nov;26(11):1453-1455. doi: 10.1016/j.cmi.2020.07.037. Epub 2020 Aug 6. PMID: 32768492. <https://www.sciencedirect.com/science/article/abs/pii/S1198743X20304456?via%3Dihub>

19. Schön T, Werngren J, Machado D, Borroni E, Wijkander M, Lina G, Mouton J, Matuschek E, Kahlmeter G, Giske C, Santin M, Cirillo DM, **Viveiros M**, Cambau E. Antimicrobial susceptibility testing of *Mycobacterium tuberculosis* complex isolates - the EUCAST broth microdilution reference method for MIC determination. *Clin Microbiol Infect*. 2020 Nov;26(11):1488-1492. doi: 10.1016/j.cmi.2020.07.036.
<https://www.sciencedirect.com/science/article/pii/S1198743X20304444?via%3Dihub>
20. Verza M, Scheffer MC, Salvato RS, Schorner MA, Barazzetti FH, Machado HM, Medeiros TF, Rovaris DB, Portugal I, **Viveiros M**, Perdigão J, Kritski A, Bazzo ML. Genomic epidemiology of *Mycobacterium tuberculosis* in Santa Catarina, Southern Brazil. *Sci Rep*. 2020 Jul 30;10(1):12891. doi: 10.1038/s41598-020-69755-9. Erratum in: *Sci Rep*. 2020 Nov 2;10(1):19250.
<https://www.nature.com/articles/s41598-020-69755-9>
21. Ong CWM, Migliori GB, Raviglione M, MacGregor-Skinner G, Sotgiu G, Alffenaar JW, Tiberi S, Adlhoch C, Alonzi T, Archuleta S, Brusin S, Cambau E, Capobianchi MR, Castilletti C, Centis R, Cirillo DM, D'Ambrosio L, Delogu G, Esposito SMR, Figueroa J, Friedland JS, Ho BCH, Ippolito G, Jankovic M, Kim HY, Rosales Klintz S, Ködmön C, Lalle E, Leo YS, Leung CC, Mårtson AG, Melazzini MG, Najafi Fard S, Penttinen P, Petrone L, Petruccioli E, Pontali E, Saderi L, Santin M, Spanevello A, van Crevel R, van der Werf MJ, Visca D, **Viveiros M**, Zellweger JP, Zumla A, Goletti D. Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). *Eur Respir J*. 2020 Oct 1;56(4):2001727. doi: 10.1183/13993003.01727-2020.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527651/>
22. Perdigão J, Silva C, Maltez F, Machado D, Miranda A, Couto I, Rabna P, Florez de Sessions P, Phelan J, Pain A, McNerney R, Hibberd ML, Mokrousov I, Clark TG, **Viveiros M**, Portugal I. Emergence of multidrug-resistant *Mycobacterium tuberculosis* of the Beijing lineage in Portugal and Guinea-Bissau: a snapshot of moving clones by whole-genome sequencing. *Emerg Microbes Infect*. 2020 Dec;9(1):1342-1353. doi: 10.1080/22221751.2020.1774425.
<https://www.tandfonline.com/doi/full/10.1080/22221751.2020.1774425>
23. Rodrigues L, Cravo P, **Viveiros M**. Efflux pump inhibitors as a promising adjunct therapy against drug resistant tuberculosis: a new strategy to revisit mycobacterial targets and repurpose old drugs. *Expert Rev Anti Infect Ther*. 2020 Aug;18(8):741-757. doi: 10.1080/14787210.2020.1760845.
<https://www.tandfonline.com/doi/full/10.1080/14787210.2020.1760845>
24. Gomes BC, Honrado M, Armada A, **Viveiros M**, Rueff J, Rodrigues AS. ABC Efflux Transporters and the Circuitry of miRNAs: Kinetics of Expression in Cancer Drug Resistance. *Int J Mol Sci*. 2020 Apr 23;21(8):2985. doi: 10.3390/ijms21082985. PMID: 32340269.
<https://www.mdpi.com/1422-0067/21/8/2985>
25. Neves CP, Costa AG, Safe IP, de Souza Brito A, Jesus JS, Kritski AL, Lacerda MVG, **Viveiros M**, Cordeiro-Santos M. The role of mini-bronchoalveolar lavage fluid in the diagnosis of pulmonary tuberculosis in critically ill patients. *BMC Infect Dis*. 2020 Mar 18;20(1):229. doi: 10.1186/s12879-020-04954-3.
<https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-04954-3>
26. Borsoi AF, Paz JD, Abbadl BL, Macchi FS, Sperotto N, Pissinate K, Rambo RS, Ramos AS, Machado D, **Viveiros M**, Bizarro CV, Basso LA, Machado P. Design, synthesis, and evaluation of new 2-(quinoline-4-yloxy)acetamide-based antituberculosis agents. *Eur J Med Chem*. 2020 Apr 15;192:112179. doi: 10.1016/j.ejmech.2020.112179.
<https://www.sciencedirect.com/science/article/pii/S022352342030146X?via%3Dihub>

27. Perdigão J, Gomes P, Miranda A, Maltez F, Machado D, Silva C, Phelan JE, Brum L, Campino S, Couto I, **Viveiros M**, Clark TG, Portugal I. Using genomics to understand the origin and dispersion of multidrug and extensively drug resistant tuberculosis in Portugal. *Sci Rep*. 2020 Feb 13;10(1):2600. doi: 10.1038/s41598-020-59558-3. <https://www.nature.com/articles/s41598-020-59558-3>
28. Salvato RS, Costa ERD, Reis AJ, Schiefelbein SH, Halon ML, Barcellos RB, Unis G, Dias CF, **Viveiros M**, Portugal I, da Silva PEA, Kritski AL, Perdigão J, Rossetti MLR. First insights into circulating XDR and pre-XDR *Mycobacterium tuberculosis* in Southern Brazil. *Infect Genet Evol*. 2020 Mar;78:104127. doi: 10.1016/j.meegid.2019.104127. <https://www.sciencedirect.com/science/article/abs/pii/S1567134819303533?via%3Dihub>
29. Cá B, Fonseca KL, Sousa J, Maceiras AR, Machado D, Sanca L, Rabna P, Rodrigues PNS, **Viveiros M**, Saraiva M. Experimental Evidence for Limited in vivo Virulence of *Mycobacterium africanum*. *Front Microbiol*. 2019 Sep 10;10:2102. doi: 10.3389/fmicb.2019.02102. eCollection 2019. <https://www.frontiersin.org/articles/10.3389/fmicb.2019.02102/full>
30. Vianna JS, Machado D, Ramis IB, Silva FP, Bierhals DV, Abril MA, von Groll A, Ramos DF, Lourenço MCS, **Viveiros M**, da Silva PEA. The Contribution of Efflux Pumps in *Mycobacterium abscessus* Complex Resistance to Clarithromycin. *Antibiotics (Basel)*. 2019 Sep 18;8(3). pii: E153. doi: 10.3390/antibiotics8030153. <https://www.mdpi.com/2079-6382/8/3/153>
31. Pena E, Machado D, **Viveiros M**, Jordão S. A case report of disseminated *Mycobacterium colombiense* infection in an HIV patient. *Int J Mycobacteriol*. 2019 Jul-Sep;8(3):295-297. doi: 10.4103/ijmy.ijmy_100_19. <http://www.ijmyco.org/article.asp?issn=2212-5531;year=2019;volume=8;issue=3;spage=295;epage=297;aulast=Pena>
32. Ramis IB, Vianna JS, Silva Junior L, von Groll A, Ramos DF, Lobo MM, Zanatta N, **Viveiros M**, Silva PEAD. *In silico* and in vitro evaluation of tetrahydropyridine compounds as efflux inhibitors in *Mycobacterium abscessus*. *Tuberculosis (Edinb)*. 2019 Sep;118:101853. doi: 10.1016/j.tube.2019.07.004. <https://www.sciencedirect.com/science/article/abs/pii/S1472979219300654?via%3Dihub>
33. Tatará MB, Perdigão J, **Viveiros M**, Kritski A, Silva KED, Sacchi FPC, de Lima CC, Dos Santos PCP, Diniz JLDCG, Almeida Silva PE, Gomes P, Gomes MMQ, Cunha EAT, Lapa E Silva JR, Portugal I, Croda J, Andrade MKN. Genetic Diversity and Molecular Epidemiology of *Mycobacterium tuberculosis* in Roraima State, Brazil. *Am J Trop Med Hyg*. 2019 Oct;101(4):774-779. doi: 10.4269/ajtmh.19-0324. <http://www.ajtmh.org/content/journals/10.4269/ajtmh.19-0324>
34. Armada A, Gomes BC, **Viveiros M**, Rueff J, Rodrigues AS. Regulation of ABCB1 activity by microRNA-200c and microRNA-203a in breast cancer cells: the quest for microRNAs' involvement in cancer drug resistance. *Cancer Drug Resistance* 2019 2, 897-911. <https://cdrjournal.com/article/view/3114>
35. Phelan JE, O'Sullivan DM, Machado D, Ramos J, Oppong YEA, Campino S, O'Grady J, McNerney R, Hibberd ML, **Viveiros M**, Huggett JF, Clark TG. Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs. *Genome Med*. 2019 Jun 24;11(1):41. doi: 10.1186/s13073-019-0650-x. PMID: 31234910 <https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-019-0650-x>
36. Rossi I, Buttini F, Sonvico F, Affaticati F, Martinelli F, Annunziato G, Machado D, **Viveiros M**, Pieroni M, Bettini R. Sodium Hyaluronate Nanocomposite Respirable Microparticles to Tackle Antibiotic Resistance with Potential Application in Treatment of Mycobacterial Pulmonary Infections. *Pharmaceutics*. 2019 May 1;11(5). pii: E203. doi: 10.3390/pharmaceutics11050203. <https://www.mdpi.com/1999-4923/11/5/203>

37. Tavares AM, Garcia AC, Gama A, Abecasis AB, **Viveiros M**, Dias S. Tuberculosis care for migrant patients in Portugal: a mixed methods study with primary healthcare providers. *BMC Health Serv Res*. 2019 Apr 18;19(1):233. doi: 10.1186/s12913-019-4050-0.
<https://bmchealthservres.biomedcentral.com/track/pdf/10.1186/s12913-019-4050-0>
38. Pereira C, Gomes P, Taveira R, Silva C, Maltez F, Macedo R, Costa C, Couvin D, Rastogi N, **Viveiros M**, Perdigão J, Portugal I. Insights on the *Mycobacterium tuberculosis* population structure associated with migrants from Portuguese-speaking countries over a three-year period in Greater Lisbon, Portugal: Implications at the public health level. *Infect Genet Evol*. 2019 Jul;71:159-165. doi: 10.1016/j.meegid.2019.03.025.
<https://www.sciencedirect.com/science/article/pii/S1567134819300462?via%3Dihub>
39. Oppong YEA, Phelan J, Perdigão J, Machado D, Miranda A, Portugal I, **Viveiros M**, Clark TG, Hibberd ML. Genome-wide analysis of *Mycobacterium tuberculosis* polymorphisms reveals lineage-specific associations with drug resistance. *BMC Genomics*. 2019 Mar 29;20(1):252. doi: 10.1186/s12864-019-5615-3.
<https://bmcgenomics.biomedcentral.com/track/pdf/10.1186/s12864-019-5615-3>
40. Felicetti T, Machado D, Cannalire R, Astolfi A, Massari S, Tabarrini O, Manfroni G, Barreca ML, Cecchetti V, **Viveiros M**, Sabatini S. Modifications on C6 and C7 Positions of 3-Phenylquinolone Efflux Pump Inhibitors Led to Potent and Safe Antimycobacterial Treatment Adjuvants. *ACS Infect Dis*. 2019 Apr 4. doi: 10.1021/acsinfecdis.9b00041.
<https://pubs.acs.org/doi/10.1021/acsinfecdis.9b00041>
41. Bouceiro-Mendes R, Ortins-Pina A, Fraga A, Marques T, **Viveiros M**, Machado D, Soares-de-Almeida L, Freitas JP, Filipe P. *Mycobacterium marinum* lymphocutaneous infection. *Dermatol Online J*. 2019 Feb 15;25(2). pii: 13030/qt5bb78905.
<https://escholarship.org/uc/item/5bb78905>
42. Costa SS, Sobkowiak B, Parreira R, Edgeworth JD, **Viveiros M**, Clark TG, Couto I. Genetic Diversity of norA, Coding for a Main Efflux Pump of *Staphylococcus aureus*. *Front Genet*. 2019 Jan 9;9:710. doi: 10.3389/fgene.2018.00710. eCollection 2018.
<https://www.frontiersin.org/articles/10.3389/fgene.2018.00710/full>
43. Vianna JS, Ramis IB, Bierhals D, von Groll A, Ramos DF, Zanatta N, Lourenço MC, **Viveiros M**, Silva PEAD. Tetrahydropyridine derivative as efflux inhibitor in *Mycobacterium abscessus*. *J Glob Antimicrob Resist*. 2019 Jan 7. pii: S2213-7165(19)30002-5. doi: 10.1016/j.jgar.2018.12.020. [Epub ahead of print]
<https://www.sciencedirect.com/science/article/pii/S2213716519300025?via%3Dihub>
44. Machado D, Lecorche E, Mougari F, Cambau E, **Viveiros M**. Insights on *Mycobacterium leprae* Efflux Pumps and Their Implications in Drug Resistance and Virulence. *Front Microbiol*. 2018 Dec 13;9:3072. doi: 10.3389/fmicb.2018.03072. eCollection 2018.
<https://www.frontiersin.org/articles/10.3389/fmicb.2018.03072/full>
45. Machado D, Couto I, **Viveiros M**. Advances in the molecular diagnosis of tuberculosis: From probes to genomes. *Infect Genet Evol*. 2019 Aug;72:93-112. doi: 10.1016/j.meegid.2018.11.021.
<https://www.sciencedirect.com/science/article/pii/S156713481830933X>
46. Brynildsrud OB, Pepperell CS, Suffys P, Grandjean L, Monteserin J, Debech N, Bohlin J, Alfsnes K, Pettersson JO, Kirkeleite I, Fandinho F, da Silva MA, Perdigao J, Portugal I, **Viveiros M**, Clark T, Caws M, Dunstan S, Thai PVK, Lopez B, Ritacco V, Kitchen A, Brown TS, van Soolingen D, O'Neill MB, Holt KE, Feil EJ, Mathema B, Balloux F, Eldholm V. Global expansion of *Mycobacterium tuberculosis* lineage 4 shaped by colonial migration and local adaptation. *Science Advances*. 2018 Oct 17;4(10):eaat5869. doi: 10.1126/sciadv.aat5869. eCollection 2018 Oct.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192687/pdf/aat5869.pdf>
<http://advances.sciencemag.org/content/4/10/eaat5869/tab-pdf>

47. Machado D, Azzali E, Couto I, Costantino G, Pieroni M, **Viveiros M**. Adjuvant therapies against tuberculosis: discovery of a 2-aminothiazole targeting *Mycobacterium tuberculosis* energetics. *Future Microbiol*. 2018 Sep;13:1383-1402. doi: 10.2217/fmb-2018-0110. Epub 2018 Sep 27.
https://www.futuremedicine.com/doi/abs/10.2217/fmb-2018-0110?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=fmb
48. Sobkowiak B, Glynn JR, Houben RMGJ, Mallard K, Phelan JE, Guerra-Assunção JA, Banda L, Mzembe T, **Viveiros M**, McNerney R, Parkhill J, Crampin AC, Clark TG. Identifying mixed *Mycobacterium tuberculosis* infections from whole genome sequence data. *BMC Genomics*. 2018 Aug 14;19(1):613. doi: 10.1186/s12864-018-4988-z.
<https://bmcbgenomics.biomedcentral.com/articles/10.1186/s12864-018-4988-z>
49. Simões AS, Maia MR, Gregório J, Couto I, Asfeldt AM, Simonsen GS, Póvoa P, **Viveiros M**, Lapão LV. Participatory implementation of an antibiotic stewardship programme supported by an innovative surveillance and clinical decision-support system. *J Hosp Infect*. 2018 Jul 30. pii: S0195-6701(18)30399-2. doi: 10.1016/j.jhin.2018.07.034.
[https://linkinghub.elsevier.com/retrieve/pii/S0195-6701\(18\)30399-2](https://linkinghub.elsevier.com/retrieve/pii/S0195-6701(18)30399-2)
50. Machado D, Girardini M, **Viveiros M**, Pieroni M. Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis. *Front Microbiol*. 2018 Jul 3;9:1367. doi: 10.3389/fmicb.2018.01367. eCollection 2018.
<https://www.frontiersin.org/articles/10.3389/fmicb.2018.01367/full>
51. Deveson Lucas D, Crane B, Wright A, Han ML, Moffatt J, Bulach D, Gladman SL, Powell D, Aranda J, Seemann T, Machado D, Pacheco T, Marques T, **Viveiros M**, Nation R, Li J, Harper M, Boyce JD. Emergence of high-level colistin resistance in an *Acinetobacter baumannii* clinical isolate mediated by inactivation of the global regulator H-NS. *Antimicrob Agents Chemother*. 2018 Apr 30. pii: AAC.02442-17. doi: 10.1128/AAC.02442-17.
<http://aac.asm.org/content/early/2018/04/17/AAC.02442-17.full.pdf>
52. Ramis IB, Vianna JS, Reis AJ, von Groll A, Ramos DF, **Viveiros M**, da Silva PEA. Antimicrobial and Efflux Inhibitor Activity of Usnic Acid Against *Mycobacterium abscessus*. *Planta Med*. 2018 Jun 18. doi: 10.1055/a-0639-5412.
<https://www.thieme-connect.com/DOI/DOI?10.1055/a-0639-5412>
53. Francisco M, Costa SS, Belas A, Ramos J, Couto I, Pomba C, **Viveiros M**. First report on antimicrobial resistance and molecular characterization of *Salmonella enterica* serotype *Typhi* isolated from human specimens in Luanda, Angola. *J Glob Antimicrob Resist*. 2018 Jun;13:246-249. doi: 10.1016/j.jgar.2018.02.001. Epub 2018 Feb 9.
<https://www.sciencedirect.com/science/article/pii/S2213716518300286?via%3Dihub>
54. Simões AS, Alves DA, Gregório J, Couto I, Dias S, Póvoa P, **Viveiros M**, Gonçalves L, Lapão LV. Fighting antibiotic resistance in Portuguese Hospitals: understanding antibiotic prescription behaviors to better design antibiotic stewardship programs. *J Glob Antimicrob Resist*. 2018 Jan 30. pii: S2213-7165(18)30015-8. doi: 10.1016/j.jgar.2018.01.013.
<https://www.sciencedirect.com/science/article/pii/S2213716518300158?via%3Dihub>
55. Machado D, Antunes J, Simões A, Perdigão J, Couto I, McCusker M, Martins M, Portugal I, Pacheco T, Batista J, Toscano C, **Viveiros M**. Contribution of efflux to colistin heteroresistance in a multidrug resistant *Acinetobacter baumannii* clinical isolate. *J Med Microbiol*. 2018 May 2. doi: 10.1099/jmm.0.000741.
<http://jmm.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.000741#tab2>

56. Coll F, Phelan J, Hill-Cawthorne GA, Nair MB, Mallard K, Ali S, Abdallah AM, Alghamdi S, Alsomali M, Ahmed AO, Portelli S, Oppong Y, Alves A, Bessa TB, Campino S, Caws M, Chatterjee A, Crampin AC, Dheda K, Furnham N, Glynn JR, Grandjean L, Ha DM, Hasan R, Hasan Z, Hibberd ML, Joloba M, Jones-López EC, Matsumoto T, Miranda A, Moore DJ, Mocillo N, Panaiotov S, Parkhill J, Penha C, Perdigão J, Portugal I, Rchiad Z, Robledo J, Sheen P, Shesha NT, Sirgel FA, Sola C, Sousa EO, Streicher EM, Van Helden P, **Viveiros M**, Warren RM, McNerney R, Pain A, Clark TG. Author Correction: Genome-wide analysis of multi- and extensively drug-resistant *Mycobacterium tuberculosis*. *Nat Genet*. 2018 May;50(5):764. doi: 10.1038/s41588-018-0074-3. <https://www.nature.com/articles/s41588-018-0074-3>
57. Perdigão J, Silva C, Diniz J, Pereira C, Machado D, Ramos J, Silva H, Abilleira F, Brum C, Reis AJ, Macedo M, Scaini JL, Silva AB, Esteves L, Macedo R, Maltez F, Clemente S, Coelho E, Viegas S, Rabna P, Rodrigues A, Taveira N, Jordao L, Kritski A, E Silva JL, Mokrousov I, Couvin D, Rastogi N, Couto I, Pain A, McNerney R, Clark TG, von Groll A, Dalla-Costa ER, Rossetti ML, da Silva PEA, **Viveiros M**, Portugal I. Clonal expansion across the seas as seen through CPLP-TB database: A joint effort in cataloguing *Mycobacterium tuberculosis* genetic diversity in Portuguese-speaking countries. *Infect Genet Evol*. 2018 Mar 17. pii: S1567-1348(18)30102-3. doi: 10.1016/j.meegid.2018.03.011. [Epub ahead of print] <https://www.sciencedirect.com/science/article/pii/S1567134818301023?via%3Dihub>
58. Machado D, Perdigão J, Portugal I, Pieroni M, Silva PA, Couto I, **Viveiros M**. Efflux Activity Differentially Modulates the Levels of Isoniazid and Rifampicin Resistance among Multidrug Resistant and Monoresistant *Mycobacterium tuberculosis* Strains. *Antibiotics (Basel)*. 2018 Mar 3;7(1). pii: E18. doi: 10.3390/antibiotics7010018. <http://www.mdpi.com/2079-6382/7/1/18>
59. Costa SS, **Viveiros M**, Pomba C, Couto I. Active antimicrobial efflux in *Staphylococcus epidermidis*: building up of resistance to fluoroquinolones and biocides in a major opportunistic pathogen. *J Antimicrob Chemother*. 2018 Feb 1;73(2):320-324. doi: 10.1093/jac/dkx400. <https://academic.oup.com/jac/advance-article-abstract/doi/10.1093/jac/dkx400/4604698?redirectedFrom=fulltext>
60. Coll F, Phelan J, Hill-Cawthorne GA, Nair MB, Mallard K, Ali S, Abdallah AM, Alghamdi S, Alsomali M, Ahmed AO, Portelli S, Oppong Y, Alves A, Bessa TB, Campino S, Caws M, Chatterjee A, Crampin AC, Dheda K, Furnham N, Glynn JR, Grandjean L, Minh Ha D, Hasan R, Hasan Z, Hibberd ML, Joloba M, Jones-López EC, Matsumoto T, Miranda A, Moore DJ, Mocillo N, Panaiotov S, Parkhill J, Penha C, Perdigão J, Portugal I, Rchiad Z, Robledo J, Sheen P, Shesha NT, Sirgel FA, Sola C, Oliveira Sousa E, Streicher EM, Helden PV, **Viveiros M**, Warren RM, McNerney R, Pain A, Clark TG. Genome-wide analysis of multi- and extensively drug-resistant *Mycobacterium tuberculosis*. *Nat Genet*. 2018 Feb;50(2):307-316. doi: 10.1038/s41588-017-0029-0. Epub 2018 Jan 22. <https://www.nature.com/articles/s41588-017-0029-0>
61. Phelan J, de Sessions PF, Tientcheu L, Perdigão J, Machado D, Hasan R, Hasan Z, Bergval IL, Anthony R, McNerney R, Antonio M, Portugal I, **Viveiros M**, Campino S, Hibberd ML, Clark TG. Methylation in *Mycobacterium tuberculosis* is lineage specific with associated mutations present globally. *Sci Rep*. 2018 Jan 9;8(1):160. doi: 10.1038/s41598-017-18188-y. <https://www.nature.com/articles/s41598-017-18188-y>
62. Ramis IB, Figueiredo R, Ramos DF, Halicki PCB, von Groll A, **Viveiros M**, do Ceu Costa M, da Silva PEA. Activity of Rifabutin and Hemi-synthetic Derivatives Against *Mycobacterium abscessus*. *Med Chem*. 2018;14(4):394-399. doi: 10.2174/1573406414666171204102633. <http://www.eurekaselect.com/158037>
63. Vila-Viçosa D, Victor BL, Ramos J, Machado D, **Viveiros M**, Switala J, Loewen PC, Leitão R, Martins F, Machuqueiro M. Insights on the Mechanism of Action of INH-C10 as an Antitubercular Prodrug. *Mol Pharm*. 2017 Dec 4;14(12):4597-4605. doi: 10.1021/acs.molpharmaceut.7b00719. <http://pubs.acs.org/doi/10.1021/acs.molpharmaceut.7b00719>

64. Nakatani Y, Opel-Reading HK, Merker M, Machado D, Andres S, Kumar SS, Moradigaravand D, Coll F, Perdigão J, Portugal I, Schön T, Nair D, Devi KRU, Kohl TA, Beckert P, Clark TG, Maphalala G, Khumalo D, Diel R, Klaos K, Aung HL, Cook GM, Parkhill J, Peacock SJ, Swaminathan S, **Viveiros M**, Niemann S, Krause KL, Köser CU. Role of alanine racemase mutations in *Mycobacterium tuberculosis* D-cycloserine resistance. *Antimicrob Agents Chemother*. 2017 Oct 2. pii: AAC.01575-17. doi: 10.1128/AAC.01575-17.
<http://aac.asm.org/content/early/2017/09/26/AAC.01575-17.long>
65. Cannalire R, Machado D, Felicetti T, Santos Costa S, Massari S, Manfroni G, Barreca ML, Tabarrini O, Couto I, **Viveiros M**, Sabatini S, Cecchetti V. Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against *Mycobacterium avium*. *Eur J Med Chem*. 2017 Sep 12;140:321-330. doi: 10.1016/j.ejmech.2017.09.014.
<http://www.sciencedirect.com/science/article/pii/S0223523417306967?via%3Dihub>
66. Tavares AM, Fronteira I, Couto I, Machado D, **Viveiros M**, Abecasis AB, Dias S. HIV and tuberculosis co-infection among migrants in Europe: A systematic review on the prevalence, incidence and mortality. *PLoS One*. 2017 Sep 28;12(9):e0185526. doi: 10.1371/journal.pone.0185526. eCollection 2017.
<http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0185526>
67. Azzali E, Machado D, Kaushik A, Vacondio F, Flisi S, Cabassi CS, Lamichhane G, **Viveiros M**, Costantino G, Pieroni M. Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery. *J Med Chem*. 2017 Aug 24;60(16):7108-7122. doi: 10.1021/acs.jmedchem.7b00793.
<http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.7b00793>
68. Santos PFGD, Costa ERD, Ramalho DM, Rossetti ML, Barcellos RB, Nunes LS, Esteves LS, Rodenbusch R, Anthony RM, Bergval I, Sengstake S, **Viveiros M**, Kritski A, Oliveira MM. Detection of tuberculosis drug resistance: a comparison by *Mycobacterium tuberculosis* MLPA assay versus Genotype®MTBDRplus. *Mem Inst Oswaldo Cruz*. 2017 Jun;112(6):396-403. doi: 10.1590/0074-02760160376.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446228/pdf/0074-0276-mioc-112-6-0396.pdf>
69. Machado D, Coelho TS, Perdigão J, Pereira C, Couto I, Portugal I, Maschmann RA, Ramos DF, von Groll A, Rossetti MLR, Silva PA, **Viveiros M**. Interplay between Mutations and Efflux in Drug Resistant Clinical Isolates of *Mycobacterium tuberculosis*. *Front Microbiol*. 2017 Apr 27;8:711. doi: 10.3389/fmicb.2017.00711.
<http://journal.frontiersin.org/article/10.3389/fmicb.2017.00711/full>
70. Machado D, Fernandes L, Costa SS, Cannalire R, Manfroni G, Tabarrini O, Couto I, Sabatini S, **Viveiros M**. Mode of action of the 2-phenylquinoline efflux inhibitor PQQ4R against *Escherichia coli*. *PeerJ*. 2017 Apr 26;5:e3168. doi: 10.7717/peerj.3168
<https://peerj.com/articles/3168/>
71. Guerreiro CS, Hartz Z, Sambo L, Conceição C, Dussault G, Russo G, **Viveiros M**, Silveira H, Pita Barros P, Ferrinho P. [Scientific Research Policy for Health in Portugal: II - Facts and Suggestions]. *Acta Med Port*. 2017 Mar 31;30(3):233-242. doi: 10.20344/amp.8012.
<http://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8012>
72. Schön T, Miotto P, Köser CU, **Viveiros M**, Böttger E, Cambau E. *Mycobacterium tuberculosis* drug-resistance testing: challenges, recent developments and perspectives. *Clin Microbiol Infect*. 2017 Mar;23(3):154-160. doi: 10.1016/j.cmi.2016.10.022.
[http://www.clinicalmicrobiologyandinfection.com/article/S1198-743X\(16\)30511-0/pdf](http://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(16)30511-0/pdf)

73. Silva L Jr, Carrion LL, von Groll A, Costa SS, Junqueira E, Ramos DF, Cantos J, Seus VR, Couto I, Fernandes LD, Bonacorso HG, Martins MA, Zanatta N, **Viveiros M**, Machado KS, Almeida da Silva PE. In vitro and in silico analysis of the efficiency of tetrahydropyridines as drug efflux inhibitors in *Escherichia coli*. *Int J Antimicrob Agents*. 2017 Mar;49(3):308-314. doi:10.1016/j.ijantimicag.2016.11.024.
[http://www.ijaaonline.com/article/S0924-8579\(17\)30026-2/pdf](http://www.ijaaonline.com/article/S0924-8579(17)30026-2/pdf)
74. Guerreiro CS, Hartz Z, Sambo L, Conceição C, Dussault G, Russo G, **Viveiros M**, Silveira H, Pita Barros P, Ferrinho P. [Scientific Research Policy for Health in Portugal: I - European and National Environment]. *Acta Med Port*. 2017 Feb 27;30(2):141-147. doi: 10.20344/amp.8011.
<http://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8011>
75. Perdigão J, Clemente S, Ramos J, Masakidi P, Machado D, Silva C, Couto I, **Viveiros M**, Taveira N, Portugal I. Genetic diversity, transmission dynamics and drug resistance of *Mycobacterium tuberculosis* in Angola. *Sci Rep*. 2017 Feb 23;7:42814. doi: 10.1038/srep42814.
<http://www.nature.com/articles/srep42814>
76. Amaral L, **Viveiros M**. Thioridazine: A Non-Antibiotic Drug Highly Effective, in Combination with First Line Anti-Tuberculosis Drugs, against Any Form of Antibiotic Resistance of *Mycobacterium tuberculosis* Due to Its Multi-Mechanisms of Action. *Antibiotics (Basel)*. 2017 Jan 14;6(1). pii: E3. doi: 10.3390/antibiotics6010003.
<http://www.mdpi.com/2079-6382/6/1/3>
77. Soares A, Estevão MS, Marques MM, Kovalishyn V, Latino DA, Aires-de-Sousa J, Ramos J, **Viveiros M**, Martins F. Synthesis and Biological Evaluation of Hybrid 1,5- and 2,5-Disubstituted Indoles as Potentially New Antitubercular Agents. *Med Chem*. 2017;13(5):439-447. doi: 10.2174/1573406413666170209144003.
<http://www.eurekaselect.com/node/149956/article/synthesis-and-biological-evaluation-of-hybrid-15-and-25-disubstituted-indoles-as-potentially-new-antitubercular-agents>
78. Phelan J, O'Sullivan DM, Machado D, Ramos J, Whale AS, O'Grady J, Dheda K, Campino S, McNerney R, **Viveiros M**, Huggett JF, Clark TG. The variability and reproducibility of whole genome sequencing technology for detecting resistance to anti-tuberculous drugs. *Genome Med*. 2016 Dec 22;8(1):132. doi: 10.1186/s13073-016-0385-x.
<https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-016-0385-x>
79. Perdigão J, Clemente S, Ramos J, Masakidi P, Machado D, Silva C, Couto I, **Viveiros M**, Taveira N, Portugal I. Genetic diversity, transmission dynamics, and drug resistance of *Mycobacterium tuberculosis* in Luanda, Angola. *Int J Mycobacteriol*. 2016 Dec;5 Suppl 1:S38-S39. doi: 10.1016/j.ijmyco.2016.09.050.
<http://www.sciencedirect.com/science/article/pii/S2212553116301881?via%3Dihub>
80. Costa SS, Palma C, Kadlec K, Fessler AT, **Viveiros M**, Melo-Cristino J, Schwarz S, Couto I. Plasmid-Borne Antimicrobial Resistance of *Staphylococcus aureus* Isolated in a Hospital in Lisbon, Portugal. *Microb Drug Resist*. 2016 Dec;22(8):617-626.
<http://online.liebertpub.com/doi/pdf/10.1089/mdr.2015.0352>
81. Costa SS, Lopes E, Azzali E, Machado D, Coelho T, da Silva PE, **Viveiros M**, Pieroni M, Couto I. An Experimental Model for the Rapid Screening of Compounds with Potential Use Against Mycobacteria. *Assay Drug Dev Technol*. 2016 Nov;14(9):524-534.
<http://online.liebertpub.com/doi/pdf/10.1089/adt.2016.752>
82. Perdigão J, Maltez F, Machado D, Silva H, Pereira C, Silva C, Couto I, **Viveiros M**, Portugal I. Beyond extensively drug-resistant tuberculosis in Lisbon, Portugal: a case of linezolid resistance acquisition presenting as an iliopsoas abscess. *Int J Antimicrob Agents*. 2016 Nov;48(5):569-570. doi: 10.1016/j.ijantimicag.2016.07.026.
[http://www.ijaaonline.com/article/S0924-8579\(16\)30269-2/pdf](http://www.ijaaonline.com/article/S0924-8579(16)30269-2/pdf)

83. Simões AS, Couto I, Toscano C, Gonçalves E, Póvoa P, **Viveiros M**, Lapão LV. Prevention and Control of Antimicrobial Resistant Healthcare-Associated Infections: The Microbiology Laboratory Rocks! *Front Microbiol*. 2016 Jun 7;7:855. doi: 10.3389/fmicb.2016.00855. <http://journal.frontiersin.org/article/10.3389/fmicb.2016.00855/full>
84. Phelan JE, Coll F, Bergval I, Anthony RM, Warren R, Sampson SL, Gey van Pittius NC, Glynn JR, Crampin AC, Alves A, Bessa TB, Campino S, Dheda K, Grandjean L, Hasan R, Hasan Z, Miranda A, Moore D, Panaiotov S, Perdigao J, Portugal I, Sheen P, de Oliveira Sousa E, Streicher EM, van Helden PD, **Viveiros M**, Hibberd ML, Pain A, McNerney R, Clark TG. Recombination in pe/ppe genes contributes to genetic variation in *Mycobacterium tuberculosis* lineages. *BMC Genomics*. 2016 Feb 29;17:151. doi: 10.1186/s12864-016-2467-y. <http://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-016-2467-y>
85. Machado D, Pires D, Perdigão J, Couto I, Portugal I, Martins M, Amaral L, Anes E, **Viveiros M**. Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant *Mycobacterium tuberculosis*. *PLoS One*. 2016 Feb 26;11(2):e0149326. doi: 10.1371/journal.pone.0149326. eCollection 2016. PubMed PMID: 26919135; PubMed Central PMCID: PMC4769142. <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0149326>
86. Armada A, Martins C, Spengler G, Molnar J, Amaral L, Rodrigues AS, **Viveiros M**. Fluorimetric Methods for Analysis of Permeability, Drug Transport Kinetics, and Inhibition of the ABCB1 Membrane Transporter. *Methods Mol Biol*. 2016;1395:87-103. doi: 10.1007/978-1-4939-3347-1_7. http://link.springer.com/protocol/10.1007%2F978-1-4939-3347-1_7
87. Machado D, Cannalire R, Santos Costa S, Manfroni G, Tabarrini O, Cecchetti V, Couto I, **Viveiros M**, Sabatini S. Boosting Effect of 2-Phenylquinoline Efflux Inhibitors in Combination with Macrolides against *Mycobacterium smegmatis* and *Mycobacterium avium*. *ACS Infect Dis*. 2015 Dec 11;1(12):593-603. doi: 10.1021/acsinfecdis.5b00052. <http://pubs.acs.org/doi/pdf/10.1021/acsinfecdis.5b00052>
88. Dalla Costa ER, Vasconcelos SE, Esteves LS, Gomes HM, Gomes LL, Almeida da Silva P, Perdigão J, Portugal I, **Viveiros M**, McNerney R, Pain A, Clark TG, Rastogi N, Unis G, Rossetti ML, Suffys PN. Multidrug resistant *Mycobacterium tuberculosis* of the Latin American Mediterranean lineage wrongly identified as *Mycobacterium pinnipedii* (ST863) causing active tuberculosis in south Brazil. *J Clin Microbiol*. 2015 Dec;53(12):3805-11. pii: JCM.02012-15. <http://www.ncbi.nlm.nih.gov/pubmed/26400784>
89. Santos Costa S, **Viveiros M**, Rosato AE, Melo-Cristino J, Couto I. Impact of efflux in the development of multidrug resistance phenotypes in *Staphylococcus aureus*. *BMC Microbiol*. 2015 Oct 24;15:232. doi: 10.1186/s12866-015-0572-8. <http://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-015-0572-8>
90. Pinto-Almeida A, Mendes T, Armada A, Belo S, Carrilho E, **Viveiros M**, Afonso A. The Role of Efflux Pumps in *Schistosoma mansoni* Praziquantel Resistant Phenotype. *PLoS One*. 2015 Oct 7;10(10):e0140147. doi: 10.1371/journal.pone.0140147. <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0140147>
91. Pieroni M, Machado D, Azzali E, Santos Costa S, Couto I, Costantino G, **Viveiros M**. Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy. *J Med Chem*. 2015 Aug 13;58(15):5842-53. doi: 10.1021/acs.jmedchem.5b00428. <http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.5b00428>

92. Coll F, McNeerney R, Preston MD, Guerra-Assunção JA, Warry A, Hill-Cawthorne G, Mallard K, Nair M, Miranda A, Alves A, Perdigão J, **Viveiros M**, Portugal I, Hasan Z, Hasan R, Glynn JR, Martin N, Pain A, Clark TG. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. *Genome Med.* 2015 May 27;7(1):51. doi: 10.1186/s13073-015-0164-0.
<http://www.genomemedicine.com/content/7/1/51>
93. Rabna P, Ramos J, Ponce G, Sanca L, Mané M, Armada A, Machado D, Vieira F, Gomes VF, Martins E, Colombatti R, Riccardi F, Perdigão J, Sotero J, Portugal I, Couto I, Atouguia J, Rodrigues A, **Viveiros M**. Direct Detection by the Xpert MTB/RIF Assay and Characterization of Multi and Poly Drug-Resistant Tuberculosis in Guinea-Bissau, West Africa. *PLoS One.* 2015 May 27;10(5):e0127536. doi: 10.1371/journal.pone.0127536.
<http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0127536>
94. Coelho T., Machado D., Couto I., Maschmann R., Ramos D., von Groll A, Rossetti ML, Silva PA, **Viveiros M**. Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant *Mycobacterium tuberculosis* clinical isolates from Brazil. *Frontiers in Microbiology*, 2015. 6:330
<http://journal.frontiersin.org/article/10.3389/fmicb.2015.00330/abstract>
95. Cabral V, Luo X, Junqueira E, Costa SS., Mulhovo S, Duarte A, Couto I, Viveiros M, Ferreira MJU. Enhancing activity of antibiotics against *Staphylococcus aureus* by *Zanthoxylum capense* constituents and derivatives. *Phytomedicine* . 2015. 22:4, 469-476
<http://www.sciencedirect.com/science/article/pii/S0944711315000495#>
96. Cambau E, **Viveiros M**, Machado D, Raskine L, Ritter C, Tortoli E, Matthys V, Hoffner S, Richter E, Perez Del Molino ML, Cirillo DM, van Soolingen D, Böttger EC. Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study. *J Antimicrob Chemother.* 2015 Mar;70(3):686-96. doi: 10.1093/jac/dku438.
<http://jac.oxfordjournals.org/content/early/2014/11/11/jac.dku438.short>
97. Rodrigues L, **Viveiros M**, Aínsa JA. Measuring efflux and permeability in mycobacteria. *Methods Mol Biol.* 2015;1285:227-39. doi: 10.1007/978-1-4939-2450-9_13.
http://link.springer.com/protocol/10.1007%2F978-1-4939-2450-9_13
98. Costa P, Couto I, **Viveiros M**, Inácio J. Nested and multiplex real-time PCR using dual-labeled probes: detecting and discriminating *Mycobacterium tuberculosis* complex members in cultures and animal tissues. *Methods Mol Biol.* 2015;1247:133-43. doi: 10.1007/978-1-4939-2004-4_9.
http://link.springer.com/protocol/10.1007/978-1-4939-2004-4_9#page-1
99. Costa P, Amaro A, Ferreira AS, Machado D, Albuquerque T, Couto I, Botelho A, **Viveiros M**, Inácio J. Rapid identification of veterinary-relevant complex species using 16S rDNA, IS6110 and Regions of Difference-targeted dual-labelled hydrolysis probes. *J Microbiol Methods.* 2014 Sep 2;107C:13-22. doi: 10.1016/j.mimet.2014.08.017.
<http://www.sciencedirect.com/science/article/pii/S0167701214002516>
100. Perdigão J, Silva H, Machado D, Macedo R, Maltez F, Silva C, Jordao L, Couto I, Mallard K, Coll F, Hill-Cawthorne GA, McNeerney R, Pain A, Clark TG, **Viveiros M**, Portugal I. Unraveling *Mycobacterium tuberculosis* genomic diversity and evolution in Lisbon, Portugal, a highly drug resistant setting. *BMC Genomics.* 2014 Nov 18;15:991. doi: 10.1186/1471-2164-15-991.
<http://www.biomedcentral.com/1471-2164/15/991>

101. Costa P, Botelho A, Couto I, **Viveiros M**, Inácio J. Standing of nucleic acid testing strategies in veterinary diagnosis laboratories to uncover *Mycobacterium tuberculosis* complex members. *Front. Mol. Biosci.*, 2014 Oct 15; 1:16. doi: 10.3389/fmolb.2014.00016.
<http://journal.frontiersin.org/Journal/10.3389/fmolb.2014.00016/full>
102. Leão C, Canto A, Machado D, Sanches IS, Couto I, **Viveiros M**, Inácio J, Botelho A. Relatedness of *Mycobacterium avium* subspecies *hominissuis* clinical isolates of human and porcine origins assessed by MLVA. *Vet Microbiol.* 2014 Sep 17;173(1-2):92-100. doi: 10.1016/j.vetmic.2014.06.027.
<http://www.sciencedirect.com/science/article/pii/S0378113514003198>
103. Coll F, McNERNEY R, Guerra-Assunção JA, Glynn JR, Perdigão J, **Viveiros M**, Portugal I, Pain A, Martin N, Clark TG. A robust SNP barcode for typing *Mycobacterium tuberculosis* complex strains. *Nature Communications.* 2014 Sep 1;5:4812. doi:10.1038/ncomms5812.
<http://www.nature.com/ncomms/2014/140901/ncomms5812/full/ncomms5812.html>
104. Martins F, Santos S, Ventura C, Elvas-Leitão R, Santos L, Vitorino S, Reis M, Miranda V, Correia HF, Aires-de-Sousa J, Kovalishyn V, Latino DA, Ramos J, **Viveiros M**. Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity. *Eur J Med Chem.* 2014 Jun 23;81:119-38. doi: 10.1016/j.ejmech.2014.04.077.
<http://www.sciencedirect.com/science/article/pii/S0223523414004061>
105. Perdigão J, Macedo R, Machado D, Silva C, Jordão L, Couto I, **Viveiros M**, Portugal I. GidB mutation as a phylogenetic marker for Q1 cluster *Mycobacterium tuberculosis* isolates and intermediate-level streptomycin resistance determinant in Lisbon, Portugal. *Clin Microbiol Infect.* 2014 May;20(5):O278-84. doi: 10.1111/1469-0691.12392. doi: 10.1111/1469-0691.12392.
<http://onlinelibrary.wiley.com/doi/10.1111/1469-0691.12392/pdf>
106. Coll F, Preston M, Guerra-Assunção JF, Hill-Cawthorn G, Harris D, Perdigão J, **Viveiros M**, Portugal I, Drobniewski F, Gagneux S, Glynn JR, Pain A, Parkhill J, McNERNEY R, Martin N, Clark TG. PolyTB: A genomic variation map for *Mycobacterium tuberculosis*. *Tuberculosis.* 2014 May;94(3):346-54. doi: 10.1016/j.tube.2014.02.005.
<http://www.sciencedirect.com/science/article/pii/S1472979214203428>
107. Pedrosa P, Veigas B, Machado D, Couto I, **Viveiros M**, Baptista PV. Gold nanoprobe for multi loci assessment of multi-drug resistant tuberculosis. *Tuberculosis.* 2014 May;94(3):332-7. doi: 10.1016/j.tube.2013.12.009.
<http://www.sciencedirect.com/science/article/pii/S147297921400002X>
108. de Carvalho CC, Costa SS, Fernandes P, Couto I, **Viveiros M**. Membrane transport systems and the biodegradation potential and pathogenicity of genus *Rhodococcus*. *Front Physiol.* 2014 Apr 4; 5:133. doi: 10.3389/fphys.2014.00133.
<http://journal.frontiersin.org/Journal/10.3389/fphys.2014.00133/abstract>
109. **Viveiros M**, Pieroni M Spectinamides: a challenge, a proof, and a suggestion. *Trends in Microbiology.* 2014 Apr;22(4):170-1. doi: 10.1016/j.tim.2014.02.008.
<http://www.sciencedirect.com/science/article/pii/S0966842X14000420>
110. Machado D, Ramos J, Couto I, Cadir N, Narciso I, Coelho E, Viegas S, **Viveiros M**. Assessment of the BD MGIT TBc Identification Test for the Detection of *Mycobacterium tuberculosis* Complex in a Network of Mycobacteriology Laboratories. *BioMed Research International*, 2014;2014:398108. doi: 10.1155/2014/398108.
<http://www.hindawi.com/journals/bmri/2014/398108/abs/>

111. Martins F, Ventura C, Santos S, **Viveiros M**. QSAR Based Design of New Antitubercular Compounds: Improved Isoniazid Derivatives Against Multidrug-Resistant TB. *Curr Pharm Des.* 2014;20(27):4427-54. doi: 10.2174/1381612819666131118164434
<http://www.eurekaselect.com/118061/article>
112. Veigas B, Pedrosa P, Couto I, **Viveiros M**, Baptista PV. Isothermal DNA amplification coupled to Au-nanoprobes for detection of mutations associated to Rifampicin resistance in *Mycobacterium tuberculosis*. *J Nanobiotechnology.* 2013 Nov 25;11:38. doi: 10.1186/1477-3155-11-38. doi: 10.1186/1477-3155-11-38.
<http://www.jnanobiotechnology.com/content/11/1/38>
113. Costa P, Ferreira AS, Amaro A, Albuquerque T, Botelho A, Couto I, Cunha MV, **Viveiros M**, Inácio J. Enhanced detection of tuberculous mycobacteria in animal tissues using a semi-nested probe-based real-time PCR. *PLoS One.* 2013 Nov 21;8(11):e81337. doi: 10.1371/journal.pone.0081337.
<http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0081337>
114. Armada AM, Alexandru T, Machado D, Danko B, Hunyadi A, Dinache A, Nastasa V, Boni M, Ramos J, **Viveiros M**, Molnar J, Pascu ML, Amaral L. The In Vitro Activity of Products Formed from Exposure of Chlorpromazine to a 266nm LASER Beam Against Species of Mycobacteria of Human Interest. *In Vivo.* 2013 Sep-Oct;27(5):605-10.
<http://iv.iijournals.org/content/27/5/605.full.pdf+html>
115. Machado D, Perdigão J, Ramos J, Couto I, Portugal I, Ritter C, Boettger EC, **Viveiros M**. High-level resistance to isoniazid and ethionamide in multidrug-resistant *Mycobacterium tuberculosis* of the Lisboa family is associated with *inhA* double mutations. *J Antimicrob Chemother.* 2013 Aug;68(8):1728-32. doi: 10.1093/jac/dkt090. doi: 10.1093/jac/dkt090.
<http://jac.oxfordjournals.org/content/68/8/1728.full.pdf+html>
116. Costa SS, Mourato C, **Viveiros M**, Melo-Cristino J, Amaral L, Couto I. Description of plasmid pSM52, harbouring the gene for the Smr efflux pump, and its involvement in resistance to biocides in a meticillin-resistant *Staphylococcus aureus* strain. *Int J Antimicrob Agents.* 2013 May;41(5):490-2. doi: 10.1016/j.ijantimicag.2013.01.003. Epub 2013 Feb 21. doi: 10.1016/j.ijantimicag.2013.01.003.
<http://www.sciencedirect.com/science/article/pii/S0924857913000307>
117. Simons SO, Kristiansen JE, Hajos G, van der Laan T, Molnár J, Boeree MJ, van Ingen J, Christensen JB, **Viveiros M**, Riedl Z, Amaral L, van Soolingen D. Activity of the efflux pump inhibitor SILA 421 against drug-resistant tuberculosis. *Int J Antimicrob Agents.* 2013 1(5):488-9. doi: 10.1016/j.ijantimicag.2013.01.001.
<http://www.sciencedirect.com/science/article/pii/S0924857913000241>
118. Martins M, McCusker MP, **Viveiros M**, Couto I, Fanning S, Pagès JM, Amaral L. A Simple Method for Assessment of MDR Bacteria for Over-Expressed Efflux Pumps. *Open Microbiol J.* 2013 Mar 22;7:72-82. doi: 10.2174/1874285801307010072.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624690/pdf/TOMICROJ-7-72.pdf>
119. Costa SS, Junqueira E, Palma C, **Viveiros M**, Melo-Cristino J, Amaral L, Couto I. Resistance to Antimicrobials Mediated by Efflux Pumps in *Staphylococcus aureus*. *Antibiotics.* 2013; 2(1):83-99. doi:10.3390/antibiotics2010083.
<http://www.mdpi.com/2079-6382/2/1/83>
120. Rodrigues L, Villellas C, Bailo R, **Viveiros M**, Aínsa JA. Role of the Mmr Efflux Pump in Drug Resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother.* 2013 Feb;57(2):751-7. doi: 10.1128/AAC.01482-12.
<http://aac.asm.org/content/57/2/751.long>

121. Perdigão J, Macedo R, Silva C, Machado D, Couto I, **Viveiros M**, Jordao L, Portugal I. From multidrug-resistant to extensively drug-resistant tuberculosis in Lisbon, Portugal: the stepwise mode of resistance acquisition. *J Antimicrob Chemother.* 2013 Jan;68(1):27-33. doi: 10.1093/jac/dks371.
<http://jac.oxfordjournals.org/content/68/1/27.long>
122. Costa SS, **Viveiros M**, Amaral L, Couto I. Multidrug Efflux Pumps in *Staphylococcus aureus*: an Update. *Open Microbiol J.* 2013;7:59-71. Epub 2013 Mar 22. doi: 10.2174/1874285801307010059.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3617543/pdf/TOMICROJ-7-59.pdf>
123. Veigas B, Jacob JM, Costa MN, Santos DS, **Viveiros M**, Inácio J, Martins R, Barquinha P, Fortunato E, Baptista PV. Gold on paper-paper platform for Au-nanoprobe TB detection. *Lab Chip.* 2012 Nov 21;12(22):4802-8. doi: 10.1039/c2lc40739f.
<http://pubs.rsc.org/en/Content/ArticleLanding/2012/LC/c2lc40739f>
124. **Viveiros M**, Martins M, Rodrigues L, Machado D, Couto I, Ainsa J, Amaral L. Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs. *Expert Rev Anti Infect Ther.* 2012 Sep;10(9):983-98. doi: 10.1586/eri.12.89.
http://www.expert-reviews.com/doi/abs/10.1586/eri.12.89?url_ver=Z39.88-2003&rft_id=ori:rid:crossref.org&rft_dat=cr_pub%3dpubmed&
125. Rodrigues L, Machado D, Couto I, Amaral L, **Viveiros M**. Contribution of efflux activity to isoniazid resistance in the *Mycobacterium tuberculosis* complex. *Infect Genet Evol.* 2012 Jun;12(4):695-700. doi: 10.1016/j.meegid.2011.08.009.
<http://www.sciencedirect.com/science/article/pii/S1567134811002887>
126. Amaral L, **Viveiros M**. Why thioridazine in combination with antibiotics cures extensively drug-resistant *Mycobacterium tuberculosis* infections. *Int J Antimicrob Agents.* 2012 May;39(5):376-80. doi: 10.1016/j.ijantimicag.2012.01.012.
<http://www.ijaaonline.com/article/S0924-8579%2812%2900053-2/abstract>
127. Dymek A, Armada A, Handzlik J, **Viveiros M**, Spengler G, Molnar J, Kieć-Kononowicz K, Amaral L. The activity of 16 new hydantoin compounds on the intrinsic and overexpressed efflux pump system of *Staphylococcus aureus*. *In Vivo.* 2012 Mar-Apr;26(2):223-9.
<http://iv.iarjournals.org/content/26/2/223.long>
128. Spengler G, Rodrigues L, Martins A, Martins M, McCusker M, Cerca P, Machado L, Costa SS, Ntokou E, Couto I, **Viveiros M**, Fanning S, Molnar J, Amaral L. Genetic response of *Salmonella enterica* serotype Enteritidis to thioridazine rendering the organism resistant to the agent. *Int J Antimicrob Agents.* 2012 Jan;39(1):16-21. doi: 10.1016/j.ijantimicag.2011.08.013.
<http://www.sciencedirect.com/science/article/pii/S092485791100358X>
129. Machado D, Couto I, Perdigão J, Rodrigues L, Portugal I, Baptista P, Veigas B., Amaral L., **Viveiros M**. Contribution of efflux to the emergence of isoniazid and multidrug resistance in *Mycobacterium tuberculosis*. *PLoS One.* 2012;7(4):e34538. doi: 10.1371/journal.pone.0034538.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321020/>
130. Spengler G, Molnar J, **Viveiros M**, Amaral L. Thioridazine induces apoptosis of multidrug-resistant mouse lymphoma cells transfected with the human ABCB1 and inhibits the expression of P-glycoprotein. *Anticancer Res.* 2011 Dec;31(12):4201-5.
<http://ar.iarjournals.org/content/31/12/4201.long>
131. Costa SS, Falcão C, **Viveiros M**, Machado D, Martins M, Melo-Cristino J, Amaral L, Couto I. Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of *Staphylococcus aureus*. *BMC Microbiol.* 2011 Oct 27;11:241. doi: 10.1186/1471-2180-11-241. Erratum in: *BMC Microbiol.* 2013;13:127.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226646/>

132. Spengler G, Handzlik J, Ocsovszki I, **Viveiros M**, Kiec-Kononowicz K, Molnar J, Amaral L. Modulation of multidrug efflux pump activity by new hydantoin derivatives on colon adenocarcinoma cells without inducing apoptosis. *Anticancer Res*. 2011 Oct;31(10):3285-8.
<http://ar.iarjournals.org/content/31/10/3285.long>
133. Machado L, Spengler G, Evaristo M, Handzlik J, Molnár J, **Viveiros M**, Kiec-Kononowicz K, Amaral L. Biological activity of twenty-three hydantoin derivatives on intrinsic efflux pump system of *Salmonella enterica* serovar Enteritidis NCTC 13349. *In Vivo*. 2011 Sep-Oct;25(5):769-72.
<http://iv.iarjournals.org/content/25/5/769.long>
134. Takács D, Cerca P, Martins A, Riedl Z, Hajós G, Molnár J, **Viveiros M**, Couto I, Amaral L. Evaluation of forty new phenothiazine derivatives for activity against intrinsic efflux pump systems of reference *Escherichia coli*, *Salmonella Enteritidis*, *Enterococcus faecalis* and *Staphylococcus aureus* strains. *In Vivo*. 2011 Sep-Oct;25(5):719-24.
<http://iv.iarjournals.org/content/25/5/719.long>
135. Amaral L, Cerca P, Spengler G, Machado L, Martins A, Couto I, **Viveiros M**, Fanning S, Pagès JM. Ethidium bromide efflux by *Salmonella*: modulation by metabolic energy, pH, ions and phenothiazines. *Int J Antimicrob Agents*. 2011 Aug;38(2):140-5. doi: 10.1016/j.ijantimicag.2011.03.014.
<http://www.sciencedirect.com/science/article/pii/S0924857911001701>
136. Cerca P, Martins A, Couto I, **Viveiros M**, Amaral L. Competition between substrates of the efflux pump system of *Salmonella enteritidis*. *In Vivo*. 2011 Jul-Aug;25(4):597-602.
<http://iv.iarjournals.org/content/25/4/597.long>
137. Amaral, L., Martins M., **Viveiros, M**. Thioridazine: Alternative and Potentially Effective Therapy of the XDR-TB Patient. *Letters in Drug Design & Discovery* 2011 8(2): 130-132.
<http://www.eurekaselect.com/87327/article>
138. Martins A, Machado L, Costa S, Cerca P, Spengler G, **Viveiros M**, Amaral L. Role of calcium in the efflux system of *Escherichia coli*. *Int J Antimicrob Agents*. 2011 May;37(5):410-4. doi: 10.1016/j.ijantimicag.2011.01.010.
<http://www.sciencedirect.com/science/article/pii/S0924857911000598>
139. Martins A, Vasas A, **Viveiros M**, Molnár J, Hohmann J, Amaral L. Antibacterial properties of compounds isolated from *Carpobrotus edulis*. *Int J Antimicrob Agents*. 2011 May;37(5):438-44. doi: 10.1016/j.ijantimicag.2011.01.016.
<http://www.sciencedirect.com/science/article/pii/S0924857911000707>
140. Amaral L, **Viveiros M**, Molnar J, Kristiansen JE. Effective Therapy with the Neuroleptic Thioridazine as an Adjunct to Second Line of Defence Drugs, and the Potential that Thioridazine Offers for New Patents that Cover a Variety of "New Uses". *Recent Pat Antiinfect Drug Discov*. 2011 May;6(2):84-7. doi: 10.2174/157489111796064542.
<http://www.eurekaselect.com/88264/article>
141. Rodrigues L, Ainsa JA, Amaral L, **Viveiros M**. Inhibition of Drug Efflux in Mycobacteria with Phenothiazines and Other Putative Efflux Inhibitors. *Recent Pat Antiinfect Drug Discov*. 2011 May;6(2):118-27. doi: 10.2174/157489111796064579
<http://www.eurekaselect.com/88270/article>
142. Pascu ML, Nastasa V, Smarandache A, Militaru A, Martins A, **Viveiros M**, Boni M, Andrei IR, Pascu A, Staicu A, Molnar J, Fanning S, Amaral L. Direct Modification of Bioactive Phenothiazines by Exposure to Laser Radiation. *Recent Pat Antiinfect Drug Discov*. 2011 May;6(2):147-57. doi: 10.2174/157489111796064542.
<http://www.eurekaselect.com/88273/article>

143. Martins M, **Viveiros M**, Couto I, Costa SS, Pacheco T, Fanning S, Pagès JM, Amaral L. Identification of efflux pump-mediated multidrug-resistant bacteria by the ethidium bromide-agar cartwheel method. *In Vivo*. 2011 Mar-Apr;25(2):171-8. <http://iv.iarjournals.org/content/25/2/171.long>
144. Rodrigues L, Ramos J, Couto I, Amaral L, **Viveiros M**. Ethidium bromide transport across *Mycobacterium smegmatis* cell-wall: correlation with antibiotic resistance. *BMC Microbiol*. 2011 Feb 18;11:35. doi: 10.1186/1471-2180-11-35. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3051877/>
145. Ramalhete C, Spengler G, Martins A, Martins M, **Viveiros M**, Mulhovo S, Ferreira MJ, Amaral L. Inhibition of efflux pumps in methicillin-resistant *Staphylococcus aureus* and *Enterococcus faecalis* resistant strains by triterpenoids from *Momordica balsamina*. *Int J Antimicrob Agents*. 2011 Jan;37(1):70-4. doi: 10.1016/j.ijantimicag.2010.09.011. <http://www.sciencedirect.com/science/article/pii/S0924857910004346>
146. Spengler G, Evaristo M, Handzlik J, Serly J, Molnár J, **Viveiros M**, Kiéc-Kononowicz K, Amaral L. Biological activity of hydantoin derivatives on P-glycoprotein (ABCB1) of mouse lymphoma cells. *Anticancer Res*. 2010 Dec;30(12):4867-71. <http://ar.iarjournals.org/content/30/12/4867.long>
147. Costa SS, Ntokou E, Martins A, **Viveiros M**, Pournaras S, Couto I, Amaral L. Identification of the plasmid-encoded *qacA* efflux pump gene in methicillin-resistant *Staphylococcus aureus* (MRSA) strain HPV107, a representative of the MRSA Iberian clone. *Int J Antimicrob Agents*. 2010 Dec;36(6):557-61. doi: 10.1016/j.ijantimicag.2010.08.006. <http://www.sciencedirect.com/science/article/pii/S0924857910003559>
148. Veigas B, Machado D, Perdigão J, Portugal I, Couto I, **Viveiros M**, Baptista PV. Au-nanoprobes for detection of SNPs associated with antibiotic resistance in *Mycobacterium tuberculosis*. *Nanotechnology*. 2010 Oct 15;21(41):415101. doi: 10.1088/0957-4484/21/41/415101. <http://iopscience.iop.org/0957-4484/21/41/415101/>
149. Martins A, Spengler G, Martins M, Rodrigues L, **Viveiros M**, Davin-Regli A, Chevalier J, Couto I, Pagès JM, Amaral L. Physiological characterisation of the efflux pump system of antibiotic-susceptible and multidrug-resistant *Enterobacter aerogenes*. *Int J Antimicrob Agents*. 2010 Oct;36(4):313-8. doi: 10.1016/j.ijantimicag.2010.06.036. <http://www.sciencedirect.com/science/article/pii/S0924857910002943>
150. Kristiansen JE, Thomsen VF, Martins A, **Viveiros M**, Amaral L. Non-antibiotics reverse resistance of bacteria to antibiotics. *In Vivo*. 2010 Sep-Oct;24(5):751-4. <http://iv.iarjournals.org/content/24/5/751.long>
151. Couto I, Machado D, **Viveiros M**, Rodrigues L, Amaral L. Identification of nontuberculous mycobacteria in clinical samples using molecular methods: a 3-year study. *Clin Microbiol Infect*. 2010 Aug;16(8):1161-4. doi: 10.1111/j.1469-0691.2009.03076.x. <http://onlinelibrary.wiley.com/doi/10.1111/j.1469-0691.2009.03076.x/abstract>
152. Chevalier J, Mahamoud A, Baitiche M, Adam E, **Viveiros M**, Smarandache A, Militaru A, Pascu ML, Amaral L, Pagès JM. Quinazoline derivatives are efficient chemosensitizers of antibiotic activity in *Enterobacter aerogenes*, *Klebsiella pneumoniae* and *Pseudomonas aeruginosa* resistant strains. *Int J Antimicrob Agents*. 2010 Aug;36(2):164-8. doi: 10.1016/j.ijantimicag.2010.03.027. <http://www.sciencedirect.com/science/article/pii/S0924857910001615>
153. Amaral L, Martins A, Molnar J, Kristiansen JE, Martins M, **Viveiros M**, Rodrigues L, Spengler G, Couto I, Ramos J, Dastidar S, Fanning S, McCusker M, Pages JM. Phenothiazines, bacterial efflux pumps and targeting the macrophage for enhanced killing of intracellular XDRTB. *In Vivo*. 2010 Jul-Aug;24(4):409-24. <http://iv.iarjournals.org/content/24/4/409.long>

154. **Viveiros M**, Martins M, Couto I, Rodrigues L, Machado D, Portugal I, Amaral L. Molecular tools for rapid identification and novel effective therapy against MDRTB/XDRTB infections. *Expert Rev Anti Infect Ther*. 2010 Apr;8(4):465-80. doi: 10.1586/eri.10.20. http://www.expert-reviews.com/doi/abs/10.1586/eri.10.20?url_ver=Z39.88-2003&rft_id=ori:rid:crossref.org&rft_dat=cr_pub%3dpubmed&
155. Martins A, Vasas A, Schelz Z, **Viveiros M**, Molnár J, Hohmann J, Amaral L. Constituents of *Carpobrotus edulis* inhibit P-glycoprotein of MDR1-transfected mouse lymphoma cells. *Anticancer Res*. 2010 Mar;30(3):829-35. <http://ar.iijournals.org/content/30/3/829.long>
156. **Viveiros M**, Rodrigues L, Martins M, Couto I, Spengler G, Martins A, Amaral L. Evaluation of efflux activity of bacteria by a semi-automated fluorometric system. *Methods Mol Biol*. 2010;642:159-72. doi: 10.1007/978-1-60327-279-7_12. http://link.springer.com/protocol/10.1007%2F978-1-60327-279-7_12
157. Martins M, Couto I, **Viveiros M**, Amaral L. Identification of efflux-mediated multi-drug resistance in bacterial clinical isolates by two simple methods. *Methods Mol Biol*. 2010;642:143-57. doi: 10.1007/978-1-60327-279-7_11. http://link.springer.com/protocol/10.1007%2F978-1-60327-279-7_11
158. Rodrigues L, Sampaio D, Couto I, Machado D, Kern WV, Amaral L, **Viveiros M**. The role of efflux pumps in macrolide resistance in *Mycobacterium avium* complex. *Int J Antimicrob Agents*. 2009 Dec;34(6):529-33. doi: 10.1016/j.ijantimicag.2009.07.010. <http://www.sciencedirect.com/science/article/pii/S0924857909003653>
159. Martins A, Iversen C, Rodrigues L, Spengler G, Ramos J, Kern WV, Couto I, **Viveiros M**, Fanning S, Pages JM, Amaral L. An AcrAB-mediated multidrug-resistant phenotype is maintained following restoration of wild-type activities by efflux pump genes and their regulators. *Int J Antimicrob Agents*. 2009 Dec;34(6):602-4. doi: 10.1016/j.ijantimicag.2009.06.029. <http://www.sciencedirect.com/science/article/pii/S0924857909003549>
160. Paixão L, Rodrigues L, Couto I, Martins M, Fernandes P, de Carvalho CC, Monteiro GA, Sansonetty F, Amaral L, **Viveiros M**. Fluorometric determination of ethidium bromide efflux kinetics in *Escherichia coli*. *J Biol Eng*. 2009 Oct 16;3:18. doi: 10.1186/1754-1611-3-18. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2774284/>
161. Spengler G, Ramalheite C, Martins M, Martins A, Serly J, **Viveiros M**, Molnár J, Duarte N, Mulhovo S, Ferreira MJ, Amaral L. Evaluation of cucurbitane-type triterpenoids from *Momordica balsamina* on P-glycoprotein (ABCB1) by flow cytometry and real-time fluorometry. *Anticancer Res*. 2009 Oct;29(10):3989-93. <http://ar.iijournals.org/content/29/10/3989.long>
162. Martins A, Spengler G, Rodrigues L, **Viveiros M**, Ramos J, Martins M, Couto I, Fanning S, Pagès JM, Bolla JM, Molnar J, Amaral L. pH Modulation of efflux pump activity of multi-drug resistant *Escherichia coli*: protection during its passage and eventual colonization of the colon. *PLoS One*. 2009 Aug 17;4(8):e6656. doi: 10.1371/journal.pone.0006656. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722724/>
163. Spengler G, **Viveiros M**, Martins M, Rodrigues L, Martins A, Molnar J, Couto I, Amaral L. Demonstration of the activity of P-glycoprotein by a semi-automated fluorometric method. *Anticancer Res*. 2009 Jun;29(6):2173-7. <http://ar.iijournals.org/content/29/6/2173.long>

164. Martins M, **Viveiros M**, Ramos J, Couto I, Molnar J, Boeree M, Amaral L. SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB). *Int J Antimicrob Agents*. 2009 May;33(5):479-82. doi: 10.1016/j.ijantimicag.2008.10.028.
<http://www.sciencedirect.com/science/article/pii/S0924857908005724>
165. Martins M, **Viveiros M**, Couto I, Amaral L. Targeting human macrophages for enhanced killing of intracellular XDR-TB and MDR-TB. *Int J Tuberc Lung Dis*. 2009 May;13(5):569-73.
<http://www.ingentaconnect.com/content/iuatld/ijtld/2009/00000013/00000005/art00008?token=005113dc8dc67232d45232b5f247a6a2d574766737a283568293c62207d673f582f6b0130dc334589>
166. Spengler G, Martins A, Schelz Z, Rodrigues L, Aagaard L, Martins M, Costa SS, Couto I, **Viveiros M**, Fanning S, Kristiansen JE, Molnar J, Amaral L. Characterization of intrinsic efflux activity of *Enterococcus faecalis* ATCC29212 by a semi-automated ethidium bromide method. *In Vivo*. 2009 Jan-Feb;23(1):81-7.
<http://iv.iiarjournals.org/content/23/1/81.long>
167. Amaral L, Martins M, **Viveiros M**, Molnar J, Kristiansen JE. Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. *Curr Drug Targets*. 2008 Sep;9(9):816-9. doi: 10.2174/138945008785747798.
<http://www.eurekaselect.com/67599/article>
168. **Viveiros M**, Martins M, Couto I, Rodrigues L, Spengler G, Martins A, Kristiansen JE, Molnar J, Amaral L. New methods for the identification of efflux mediated MDR bacteria, genetic assessment of regulators and efflux pump constituents, characterization of efflux systems and screening for inhibitors of efflux pumps. *Curr Drug Targets*. 2008 Sep;9(9):760-78. doi: 10.2174/138945008785747734
<http://www.eurekaselect.com/67594/article>
169. Couto I, Costa SS, **Viveiros M**, Martins M, Amaral L. Efflux-mediated response of *Staphylococcus aureus* exposed to ethidium bromide. *J Antimicrob Chemother*. 2008 Sep;62(3):504-13. doi: 10.1093/jac/dkn217.
<http://jac.oxfordjournals.org/content/62/3/504.long>
170. **Viveiros M**, Martins A, Paixão L, Rodrigues L, Martins M, Couto I, Fähnrich E, Kern WV, Amaral L. Demonstration of intrinsic efflux activity of *Escherichia coli* K-12 AG100 by an automated ethidium bromide method. *Int J Antimicrob Agents*. 2008 May;31(5):458-62. doi: 10.1016/j.ijantimicag.2007.12.015.
<http://www.sciencedirect.com/science/article/pii/S0924857908000320>
171. Rodrigues L, Wagner D, **Viveiros M**, Sampaio D, Couto I, Vavra M, Kern WV, Amaral L. Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in *Mycobacterium avium* and *Mycobacterium smegmatis*. *J Antimicrob Chemother*. 2008 May;61(5):1076-82. doi: 10.1093/jac/dkn070.
<http://jac.oxfordjournals.org/content/61/5/1076.long>
172. Martins M, **Viveiros M**, Amaral L. The TB laboratory of the future: macrophage-based selection of XDR-TB therapeutics. *Future Microbiol*. 2008 Apr;3:135-44. doi: 10.2217/17460913.3.2.135.
http://www.futuremedicine.com/doi/abs/10.2217/17460913.3.2.135?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed&
173. Martins M, Dastidar SG, Fanning S, Kristiansen JE, Molnar J, Pagès JM, Schelz Z, Spengler G, **Viveiros M**, Amaral L. Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities. *Int J Antimicrob Agents*. 2008 Mar;31(3):198-208. doi: 10.1016/j.ijantimicag.2007.10.025.
<http://www.sciencedirect.com/science/article/pii/S0924857907005572>

174. Martins M, **Viveiros M**, Amaral L. Inhibitors of Ca²⁺ and K⁺ transport enhance intracellular killing of *M. tuberculosis* by non-killing macrophages. *In Vivo*. 2008 Jan-Feb;22(1):69-75.
<http://iv.iijournals.org/content/22/1/69.long>
175. Martins M, **Viveiros M**, Kristiansen JE, Molnar J, Amaral L. The curative activity of thioridazine on mice infected with *Mycobacterium tuberculosis*. *In Vivo*. 2007 Sep-Oct;21(5):771-5.
<http://iv.iijournals.org/content/21/5/771.long>
176. Amaral L, Martins M, **Viveiros M**. Phenothiazines as anti-multi-drug resistant tubercular agents. *Infect Disord Drug Targets*. 2007 Sep;7(3):257-65. doi: 10.2174/187152607782110022
<http://www.eurekaselect.com/78873/article>
177. Schelz Z, Martins M, Martins A, **Viveiros M**, Molnar J, Amaral L. Elimination of plasmids by SILA compounds that inhibit efflux pumps of bacteria and cancer cells. *In Vivo*. 2007 Jul-Aug;21(4):635-9.
<http://iv.iijournals.org/content/21/4/635.long>
178. Duarte N, Ferreira MJ, Martins M, **Viveiros M**, Amaral L. Antibacterial activity of ergosterol peroxide against *Mycobacterium tuberculosis*: dependence upon system and medium employed. *Phytother Res*. 2007 Jul;21(7):601-4. doi: 10.1002/ptr.2119.
<http://onlinelibrary.wiley.com/doi/10.1002/ptr.2119/abstract;jsessionid=44FB2432A6DF4040AEEBEEA16502FFC3.d04t04>
179. Amaral L, Martins M, **Viveiros M**. Enhanced killing of intracellular multidrug-resistant *Mycobacterium tuberculosis* by compounds that affect the activity of efflux pumps. *J Antimicrob Chemother*. 2007 Jun;59(6):1237-46. doi: 10.1093/jac/dkl500.
<http://jac.oxfordjournals.org/content/59/6/1237.long>
180. **Viveiros M**, Dupont M, Rodrigues L, Couto I, Davin-Regli A, Martins M, Pagès JM, Amaral L. Antibiotic stress, genetic response and altered permeability of *Escherichia coli*. *PLoS One*. 2007 Apr 11;2(4):e365. doi: 10.1371/journal.pone.0000365.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1838523/>
181. Amaral L, Engi H, **Viveiros M**, Molnar J. Review. Comparison of multidrug resistant efflux pumps of cancer and bacterial cells with respect to the same inhibitory agents. *In Vivo*. 2007 Mar-Apr;21(2):237-44.
<http://iv.iijournals.org/content/21/2/237.long>
182. Martins A, Couto I, Aagaard L, Martins M, **Viveiros M**, Kristiansen JE, Amaral L. Prolonged exposure of methicillin-resistant *Staphylococcus aureus* (MRSA) COL strain to increasing concentrations of oxacillin results in a multidrug-resistant phenotype. *Int J Antimicrob Agents*. 2007 Mar;29(3):302-5. Epub 2007 Feb 2. doi:10.1016/j.ijantimicag.2006.10.012.
<http://www.sciencedirect.com/science/article/pii/S0924857906004730>
183. Martins M, Schelz Z, Martins A, Molnar J, Hajös G, Riedl Z, **Viveiros M**, Yalcin I, Aki-Sener E, Amaral L. In vitro and ex vivo activity of thioridazine derivatives against *Mycobacterium tuberculosis*. *Int J Antimicrob Agents*. 2007 Mar;29(3):338-40. doi:10.1016/j.ijantimicag.2006.10.013.
<http://www.sciencedirect.com/science/article/pii/S0924857906004742>
184. Martins M, Santos B, Martins A, **Viveiros M**, Couto I, Cruz A, Pagès JM, Molnar J, Fanning S, Amaral L Management Committee Members; of Cost B16; European Commission/European Science Foundation. An instrument-free method for the demonstration of efflux pump activity of bacteria. *In Vivo*. 2006 Sep-Oct;20(5):657-64.
<http://iv.iijournals.org/content/20/5/657.long>

185. Martins M, **Viveiros M**, Ordway D, Kristiansen JE, Molnár J, Amaral L. Reserpine, Ouabain and the Calcium Channel Blocker Verapamil, cause intracellular killing of *Staphylococcus aureus*. *Research Journal of Microbiology*. 2006 1(3):203-209. doi: jm.2006.203.209. <http://scialert.net/qredirect.php?doi=jm.2006.203.209&linkid=pdf>
186. Amaral L, **Viveiros M**, Kristiansen JE. "Non-Antibiotics": alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries. *Curr Drug Targets*. 2006 Jul;7(7):887-91. doi: 10.2174/13894500677709539. <http://www.eurekaselect.com/56303/article>
187. Wolfart K, Spengler G, Kawase M, Motohashi N, Molnár J, **Viveiros M**, Amaral L. Synergistic interaction between proton pump inhibitors and resistance modifiers: promoting effects of antibiotics and plasmid curing. *In Vivo*. 2006 May-Jun;20(3):367-72. <http://iv.iijournals.org/content/20/3/367.long>
188. Kristiansen MM, Leandro C, Ordway D, Martins M, **Viveiros M**, Pacheco T, Molnar J, Kristiansen JE, Amaral L. Thioridazine reduces resistance of methicillin-resistant *Staphylococcus aureus* by inhibiting a reserpine-sensitive efflux pump. *In Vivo*. 2006 May-Jun;20(3):361-6. <http://iv.iijournals.org/content/20/3/361.long>
189. Ordway D. J., **Viveiros M.**, Ventura F. A., Orme I. M., Dockrell H. M. and Amaral L. Exogenous re-infection by multiple exposures to *Mycobacterium tuberculosis* contributes to subsequent development of active tuberculosis. *American Journal of Immunology* 2005 1(1): 42-47. doi: 10.3844/ajisp.2005.42.47 <http://thescipub.com/abstract/10.3844/ajisp.2005.42.47>
190. **Viveiros M**, Leandro C, Rodrigues L, Almeida J, Bettencourt R, Couto I, Carrilho L, Diogo J, Fonseca A, Lito L, Lopes J, Pacheco T, Pessanha M, Quirim J, Sancho L, Salfinger M, Amaral L. Direct application of the INNO-LiPA Rif.TB line-probe assay for rapid identification of *Mycobacterium tuberculosis* complex strains and detection of rifampin resistance in 360 smear-positive respiratory specimens from an area of high incidence of multidrug-resistant tuberculosis. *J Clin Microbiol*. 2005 Sep;43(9):4880-4. doi: 10.1128/JCM.43.9.4880-4884.2005. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1234138/>
191. **Viveiros M**, Jesus A, Brito M, Leandro C, Martins M, Ordway D, Molnar AM, Molnar J, Amaral L. Inducement and reversal of tetracycline resistance in *Escherichia coli* K-12 and expression of proton gradient-dependent multidrug efflux pump genes. *Antimicrob Agents Chemother*. 2005 Aug;49(8):3578-82. doi: 10.1128/AAC.49.8.3578-3582.2005. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1196278/>
192. **Viveiros M**, Martins M, Couto I, Kristiansen JE, Molnar J, Amaral L. The in vitro activity of phenothiazines against *Mycobacterium avium*: potential of thioridazine for therapy of the co-infected AIDS patient. *In Vivo*. 2005 Jul-Aug;19(4):733-6. <http://iv.iijournals.org/content/19/4/733>
193. Ordway DJ, Pinto L, Costa L, Martins M, Leandro C, **Viveiros M**, Amaral L, Arroz MJ, Ventura FA, Dockrell HM. Gamma delta T cell responses associated with the development of tuberculosis in health care workers. *FEMS Immunol Med Microbiol*. 2005 Mar 1;43(3):339-50. doi: 10.1016/j.femsim.2004.09.005. <http://onlinelibrary.wiley.com/doi/10.1016/j.femsim.2004.09.005/abstract>
194. Martins M, Ordway D, Kristiansen M, **Viveiros M**, Leandro C, Molnar J, Amaral L. Inhibition of the *Carpobrotus edulis* methanol extract on the growth of phagocytosed multidrug-resistant *Mycobacterium tuberculosis* and methicillin-resistant *Staphylococcus aureus*. *Fitoterapia*. 2005 Jan;76(1):96-9. doi:10.1016/j.fitote.2004.09.020. <http://www.sciencedirect.com/science/article/pii/S0367326X0400228X>

195. Martins M, Bleiss W, Marko A, Ordway D, **Viveiros M**, Leandro C, Pacheco T, Molnar J, Kristiansen JE, Amaral L. Clinical concentrations of thioridazine enhance the killing of intracellular methicillin-resistant *Staphylococcus aureus*: an in vivo, ex vivo and electron microscopy study. *In Vivo*. 2004 Nov-Dec;18(6):787-94.
<http://iv.iijournals.org/content/18/6/787>
196. Amaral L, **Viveiros M**, Molnar J. Antimicrobial activity of phenothiazines. *In Vivo*. 2004 Nov-Dec;18(6):725-31.
<http://iv.iijournals.org/content/18/6/725>
197. Grácio MA, Grácio AJ, **Viveiros M**, Amaral L. Since phenothiazines alter antibiotic susceptibility of microorganisms by inhibiting efflux pumps, are these agents useful for evaluating similar pumps in phenothiazine-sensitive parasites? *Int J Antimicrob Agents*. 2003 Sep;22(3):347-51. doi:10.1016/S0924-8579(03)00204-8.
<http://www.sciencedirect.com/science/article/pii/S0924857903002048>
198. **Viveiros M**, Leandro C, Amaral L. Mycobacterial efflux pumps and chemotherapeutic implications. *Int J Antimicrob Agents*. 2003 Sep;22(3):274-8. doi:10.1016/S0924-8579(03)00208-5.
<http://www.sciencedirect.com/science/article/pii/S0924857903002085>
199. Kristiansen MM, Leandro C, Ordway D, Martins M, **Viveiros M**, Pacheco T, Kristiansen JE, Amaral L. Phenothiazines alter resistance of methicillin-resistant strains of *Staphylococcus aureus* (MRSA) to oxacillin in vitro. *Int J Antimicrob Agents*. 2003 Sep;22(3):250-3. doi:10.1016/S0924-8579(03)00200-0.
<http://www.sciencedirect.com/science/article/pii/S0924857903002000>
200. Ordway D, Hohmann J, **Viveiros M**, Viveiros A, Molnar J, Leandro C, Arroz MJ, Gracio MA, Amaral L. *Carpobrotus edulis* methanol extract inhibits the MDR efflux pumps, enhances killing of phagocytosed *S. aureus* and promotes immune modulation. *Phytother Res*. 2003 May;17(5):512-9. doi: 10.1002/ptr.1314.
<http://onlinelibrary.wiley.com/doi/10.1002/ptr.1314/abstract>
201. Ordway D, **Viveiros M**, Leandro C, Bettencourt R, Almeida J, Martins M, Kristiansen JE, Molnar J, Amaral L. Clinical concentrations of thioridazine kill intracellular multidrug-resistant *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother*. 2003 Mar;47(3):917-22. doi: 10.1128/AAC.47.3.917-922.2003.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC149316/>
202. **Viveiros M**, Portugal I, Bettencourt R, Victor TC, Jordaan AM, Leandro C, Ordway D, Amaral L. Isoniazid-induced transient high-level resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother*. 2002 Sep;46(9):2804-10. doi: 10.1128/AAC.46.9.2804-2810.2002.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC127392/>
203. Ordway D, **Viveiros M**, Leandro C, Jorge Arroz M, Molnar J, Kristiansen JE, Amaral L. Chlorpromazine has intracellular killing activity against phagocytosed *Staphylococcus aureus* at clinical concentrations. *J Infect Chemother*. 2002 Sep;8(3):227-31.
<http://link.springer.com/article/10.1007/s10156-002-0188-4>
204. Ordway D, **Viveiros M**, Leandro C, Arroz MJ, Amaral L. Intracellular activity of clinical concentrations of phenothiazines including thioridazine against phagocytosed *Staphylococcus aureus*. *Int J Antimicrob Agents*. 2002 Jul;20(1):34-43. doi:10.1016/S0924-8579(02)00110-3
<http://www.sciencedirect.com/science/article/pii/S0924857902001103>

205. Amaral L, **Viveiros M**, Kristiansen JE. Phenothiazines: potential alternatives for the management of antibiotic resistant infections of tuberculosis and malaria in developing countries. *Trop Med Int Health*. 2001 Dec;6(12):1016-22. doi: 10.1046/j.1365-3156.2001.00804.x
<http://onlinelibrary.wiley.com/doi/10.1046/j.1365-3156.2001.00804.x/abstract;jsessionid=4DA2BBC8BBB68AFB65EEA6DD1AF71962.d04t04>
206. Amaral L, Kristiansen JE, **Viveiros M**, Atouguia J. Activity of phenothiazines against antibiotic-resistant *Mycobacterium tuberculosis*: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. *J Antimicrob Chemother*. 2001 May;47(5):505-11. doi: 10.1093/jac/47.5.505.
<http://jac.oxfordjournals.org/content/47/5/505.long>
207. **Viveiros M**, Amaral L. Enhancement of antibiotic activity against poly-drug resistant *Mycobacterium tuberculosis* by phenothiazines. *Int J Antimicrob Agents*. 2001 Mar;17(3):225-8. doi:10.1016/S0924-8579(00)00343-5.
<http://www.sciencedirect.com/science/article/pii/S0924857900003435>
208. **Viveiros-Bettencourt M**, Bosne-David S, Amaral L. Comparative in vitro activity of phenothiazines against multidrug-resistant *Mycobacterium tuberculosis*. *Int J Antimicrob Agents*. 2000 Sep;16(1):69-71. doi:10.1016/S0924-8579(00)00199-0.
<http://www.sciencedirect.com/science/article/pii/S0924857900001990>
209. **Viveiros M**, Krubasik P, Sandmann G, Houssaini-Iraqi M. Structural and functional analysis of the gene cluster encoding carotenoid biosynthesis in *Mycobacterium aurum* A+. *FEMS Microbiol Lett*. 2000 Jun 1;187(1):95-101. doi:10.1016/S0378-1097(00)00182-8
<http://www.sciencedirect.com/science/article/pii/S0378109700001828>
210. **Viveiros M**, Pinheiro S, Moreira P, Pacheco T, Brum L. Evaluation of a commercial ligase chain reaction assay for the diagnosis of pulmonary and extra-pulmonary tuberculosis. *Int J Tuberc Lung Dis*. 1999 Jun;3(6):508-14.
<http://www.ingentaconnect.com/content/iuatld/ijtld/1999/00000003/00000006/art00009?token=005e1dff1499aeaa8229e41333c4a2f7a3f6a2d2c2046547d3f3c624f6d6222346b626876305021f35b4fecf65e4f7>
211. **Portugal I**, Covas MJ, Brum L, Viveiros M, Ferrinho P, Moniz-Pereira J, David HL. Outbreak of multiple drug-resistant tuberculosis in Lisbon: detection by restriction fragment length polymorphism analysis. *Int J Tuberc Lung Dis*. 1999 Mar;3(3):207-13.
<http://www.ingentaconnect.com/content/iuatld/ijtld/1999/00000003/00000003/art00007?token=004f1aa34d6178d2ea573d257025702c236e2f5f3172767c2b657c4e75477e4324576b6427386fa>
212. Ribeiro G, **Viveiros M**, David HL, Costa JV. Mycobacteriophage D29 contains an integration system similar to that of the temperate mycobacteriophage L5. *Microbiology*. 1997 Aug;143 (Pt 8):2701-8. doi: 10.1099/00221287-143-8-2701
<http://mic.sgmjournals.org/content/143/8/2701.long>

PUBLICATIONS IN NATIONAL PEER-REVIEW JOURNALS (N = 11):

1. Bouceiro-Mendes R, Ortins-Pina A, Marques T, **Viveiros M**, Machado D, Lito L, Ferreira J, Soares-de-Almeida L, Freitas JP, Filipe P. A case report of multibacillary leprosy presenting with multiple outbreaks of erythema nodosum leprosum. 2019. *Journal of the Portuguese Society of Dermatology and Venereology*. 77(1):67-72.
<https://revista.spdv.com.pt/index.php/spdv/article/view/1015/622>
2. Perdigão J., Silva C., Diniz J., Pereira C., Machado D., Ramos J., Silva H., Abilleira F., Brum C., Reis A.J., Macedo M., Scaini, J.I., Silva A. B., Esteves L., Macedo R., Maltez F., Clemente S., Coelho E., Viegas S., Rabna P., Rodrigues A., Taveira N., Jordão L., Kritski A., Lapa J., Mokrousov I., Couvin D., Rastogi N., Couto I., Pain A., McNerney R., Clark T. G., von Groll A., Dalla-Costa E.R., Rossetti M.L., da Silva P.E.A., **Viveiros M.**, Portugal I. CPLP-TB: uma nova ferramenta de vigilância transnacional da tuberculose no espaço lusófono. 2018. *Anais do Instituto de Higiene e Medicina Tropical* 17, 87-90.
<https://anaisihmt.com/index.php/ihmt/article/download/278/230>
3. Morais S.A., Moneti V., Silva J., Pereira K., Manso M., Santos T.V., Falcão V, Miranda A, Antunes I, Machado D, **Viveiros M**, Rijo J, Batista J, Mansinho K. Tuberculose extensivamente resistente: uma realidade presente. Revisão da literatura a propósito de um caso clínico. 2017. *RPDI-Revista Portuguesa de Doenças Infecciosas* 13 (1).
http://spdimc.org/wp/wp-content/uploads/2017/07/RPDI_13-1.pdf
4. Conceição C, **Viveiros M**, Cruz D, Pinto JR. 4th National Congress of Tropical Medicine-Chronic respiratory diseases and tuberculosis pre-congress seminar. 2017. *Anais do Instituto de Higiene e Medicina Tropical* 16, 23-29
<http://anaisihmt.com/index.php/ihmt/article/download/23/17/>
5. **Viveiros M.**, Matos O. 4th National Congress of Tropical Medicine and 1st Lusophone Meeting on AIDS, Tuberculosis and Opportunistic Diseases. 2017. *Anais do Instituto de Higiene e Medicina Tropical* 16, 7-14
<http://anaisihmt.com/index.php/ihmt/article/download/20/15>
6. **Viveiros M.**, Simões M.J., Pequena história da RIDES-Tuberculose no âmbito do Plano Estratégico de Cooperação em Saúde 2009-2012 da Comunidade dos Países de Língua Portuguesa. 2016. *Anais do Instituto de Higiene e Medicina Tropical*. 15, 45-50
<https://anaisihmt.com/index.php/ihmt/article/download/104/86>
7. **Viveiros M.**, Couto I., Breve história da micobacteriologia no IHMT/UNL. 2014. *Anais do Instituto de Higiene e Medicina Tropical*. 13, 29-35.
<https://anaisihmt.com/index.php/ihmt/article/download/168/136>
8. **Viveiros M.**, O Ensino das Ciências Médicas e Biomédicas no Instituto de Higiene e Medicina Tropical – A Contextualização Histórico-Pedagógica. 2012. *Anais do Instituto de Higiene e Medicina Tropical* 11, 178-180
<http://anaisihmt.com/index.php/ihmt/article/download/233/194>
9. Castro R., Costa J., Couto I., Vieira M.L., **Viveiros M**. Infecções Bacterianas Negligenciadas, Esquecidas ou Desconhecidas? A Tradição Exótica do IHMT. 2012. *Anais do Instituto de Higiene e Medicina Tropical* 11, 60-65
<http://anaisihmt.com/index.php/ihmt/article/download/212/174>
10. Rodrigues G., Corredoura A.S., Moraes M.F., Oliveira L., Pinheiro M.N., Da Graça J.P., **Viveiros M.**, Brum L, Pacheco T, Aguiar P, Abecasis P. Estudo da resposta aos antibióticos em doentes com infecção VIH.2000. *Revista Portuguesa de Pneumologia* 6 (2), 115-122
<https://www.sciencedirect.com/science/article/pii/S0873215915308795>

11. Prieto E., Pacheco T., **Viveiros M.**, Bettencourt R., Brum L., Exposto F. Pesquisa de infecção micobacteriana em hemoculturas de doentes com SIDA, usando o sistema BACTEC 460 TB. 1996. Revista Portuguesa de Pneumologia 2 (6), 403-407
https://www.sciencedirect.com/science/article/pii/S0873215915311788/pdf?md5=61b38e4c0c25f4b965d59998493ea05d&isDTMRedir=Y&pid=1-s2.0-S0873215915311788-main.pdf&_valck=1

BOOKS AND BOOK CHAPTERS (N = 23):

1. Ordway DJ, **Viveiros M**, Ventura FA., Dockrell HM, Amaral L. (2005) Does multiple exposure to *Mycobacterium tuberculosis* lead to reduction of a Th1 immune response and concomitant presence of Th2 immune response which contributes to subsequent development of active tuberculosis? In: Research Advances in Infectious Diseases, Mohan R.M. editor, Global Research Network, Kerala, India, p.15-34.
2. **Viveiros M**, Leandro C, Rodrigues L, Almeida J, Bettencourt R, Couto I, Carrilho L, Diogo J, Fonseca A, Lito L, Lopes J, Pacheco T, Pessanha M, Quirim J, Sancho L, Salfinger M. (2006). Diagnóstico precoce da tuberculose multirresistente (TBMR): O Programa Faster-Track de Combate à Tuberculose Multirresistente na Grande Lisboa. In: Tuberculose - Impacto da Infecção VIH. Jaime Pina editor, Sociedade Portuguesa de Pneumologia - Hospital Pulido Valente – GlaxoSmithKline, Lisboa, Portugal, p.83-99.
3. **Viveiros M**, Atouguia J. (2008) Tuberculose – Saúde Tropical. Edição Universidade Aberta (ISBN:978-972-674-494-8) 155 pp.
<http://loja.uab.pt/scripto/textos-de-cursos-nao-formais/produto/tuberculose- 1368.aspx>
4. **Viveiros M**. (2010) Segurança no Laboratório de Microbiologia In: Microbiologia (1ª Edição), Wanda F. Canas Ferreira, João Carlos F. de Sousa and Nelson Lima editores, Lidel, Edições Técnicas, Lisboa, Portugal. pp. - 588-609 (ISBN 9789727575152)
http://www.fca.pt/cgi-bin/lidel_main.cgi/?op=3&mnu=100&edicao=1&isbn=978-972-757-515-2
5. **Viveiros M.**, Rodrigues L., Martins M., Couto I., Martins A., Spengler G. and Amaral L. (2009) Evaluation of efflux activity of bacteria by an ethidium bromide semi-automated fluorometric system. In: Antibiotic Resistance Protocols for Methods in Molecular Medicine Series, Second Edition. John Walker editor. Humana Press, Springer Science+Business Media, LLC. Londres, Reino Unido. pp. 159-172. (ISBN 978-1-60327-278-0).
http://www.springerprotocols.com/Abstract/doi/10.1007/978-1-60327-279-7_12
6. Martins M, Couto I, **Viveiros M**, Amaral L (2009) Identification of efflux-mediated multi-drug resistance in bacterial clinical isolates by two simple methods. In: Antibiotic Resistance Protocols for Methods in Molecular Medicine Series, Second Edition. John Walker editor. Humana Press, Springer Science+Business Media, LLC. Londres, Reino Unido. pp. 143-157 (ISBN 978-1-60327-278-0).
http://www.springerprotocols.com/Abstract/doi/10.1007/978-1-60327-279-7_12
7. Amaral L, Fanning S, Spengler G, Rodrigues L, Iversen C, Martins M, Martins A, **Viveiros M**, Couto I. (2009) Genetic regulation, physiology, assessment and inhibition of efflux pumps responsible for multi-drug resistant phenotypes of bacterial pathogens (I) In: Antibiotic Resistance. 1st Edition_eBook. Agoston Meszaros and Gusztav Balogh editors. NovaScience, Nova York, EUA. (ISBN 978-1-61668-162-3).
https://www.novapublishers.com/catalog/product_info.php?products_id=12660
8. Amaral L, Fanning S, Spengler G, Rodrigues L, Iversen C, Martins M, Martins A, **Viveiros M**, Couto I. (2011) Genetic regulation, physiology, assessment and inhibition of efflux pumps responsible for multi-drug resistant phenotypes of bacterial pathogens (II) In: Antibiotic Resistance: Causes and Risk Factors, Mechanisms and Alternatives. 2nd Edition_Hardcover. Adriel R. Bonilla and Kaden P. Muniz editors. NovaScience, Nova York, EUA. pp. 313-332. (ISBN 978-1-60741-623-4).
https://www.novapublishers.com/catalog/product_info.php?products_id=10081

9. Amaral L, Fanning S, Spengler G, Rodrigues L, Iversen C, Martins M, Martins A, **Viveiros M**, Couto I. (2011) Genetic regulation, physiology, assessment and inhibition of efflux pumps responsible for multi-drug resistant phenotypes of bacterial pathogens (III) In: Multiple Drug Resistance. Agoston Meszaros and Gusztav Balogh editors. NovaScience, Nova York, EUA. 312 pags.. (ISBN 978-1-60741-595-4).
https://www.novapublishers.com/catalog/product_info.php?products_id=10044
10. Amaral L, Fanning S, Spengler G, Rodrigues L, Iversen C, Martins M, Martins A, **Viveiros M**, Couto I. (2012) Genetic regulation, physiology, assessment and inhibition of efflux pumps responsible for multi-drug resistant phenotypes of bacterial pathogens (IV) In: Bacterial Pathogens: Virulence Mechanisms, Diagnosis and Management. Aimee Boulanger and Maison Blanc editors. NovaScience, Nova York, EUA. pp. 66-85. (ISBN 978-1-62081-887-9).
https://www.novapublishers.com/catalog/product_info.php?products_id=30993
11. **Viveiros M**. (2012) A Importância da Biossegurança Como Disciplina Curricular. In Workshop Biossegurança: Situação em Portugal. Sofia Nuncio, Ana Pelerito, Rita Cordeiro editors. Ministério da Saúde. Instituto Nacional de Saúde Doutor Ricardo Jorge, IP, Lisboa, Portugal. pp. 13-17. (ISBN: 978-972-8643-75-1).
<http://repositorio.insa.pt/bitstream/10400.18/1538/3/Workshop%20Biosseguran%C3%A7a%20-%20Situa%C3%A7%C3%A3o%20em%20Portugal.pdf>
12. Amaral L, Martins A, Spengler G, Martins M, McCusker M, **Viveiros M**, Fanning S, Molnar J. (2013) Structure, Genetic Regulation, Physiology and Function of the AcrAB-TolC Efflux Pump of *Escherichia coli* and *Salmonella*. In: Antimicrobial Drug Discovery-Emerging Strategies. George Tegos and E Mylonakis, editors. CABI Publishing, Oxfordshire, UK, pp. 44-61. (ISBN 781-84593-943-4).
<http://bookshop.cabi.org/default.aspx?site=191&page=2633&pid=2443>
13. **Viveiros M**, Machado D, Couto I, Amaral L (2013) Improving on the LJ slope – automated liquid culture. In: Tuberculosis - Diagnosis and Treatment (Advances in Molecular and Cellular Microbiology Series) T D McHugh, editor. CABI Publishing, Oxfordshire, UK, 304 pag. (ISBN 781-84593-807-9).
<http://bookshop.cabi.org/?page=2633&pid=2372&site=191>
14. Amaral L, Martins M, Couto I, **Viveiros M** (2013) Therapy of the XDR-TB Patients with Thioridazine - an Old Drug with New Applications. In: Tuberculosis - Diagnosis and Treatment (Advances in Molecular and Cellular Microbiology Series) T D McHugh, editor. CABI Publishing, Oxfordshire, UK, 304 pag. (ISBN 781-84593-807-9).
<http://bookshop.cabi.org/?page=2633&pid=2372&site=191>
15. **Viveiros M**, Couto I, Inácio J. (2014) Diagnóstico Molecular. In: Microbiologia Médica, António Meliço-Silvestre, Helena Barroso and Nuno Taveira editores, Lidel, Edições Técnicas, Lisboa, Portugal. (ISBN - 978-972-757-576-3).
https://www.fca.pt/cgi-bin/lidel_main.cgi?op=3&mnu=100&edicao=1&isbn=978-989-752-057-0&novidade=0
http://issuu.com/lidel/docs/microbiologia_medica_volume_1?mode=embed&layout=http%3A%2F%2Fskin.issuu.com%2Fv%2Flight%2Flayout.xml&showFlipBtn=true
16. Portugal I, **Viveiros M**. (2014) *Mycobacterium* In: Microbiologia Médica, António Meliço-Silvestre, Helena Barroso and Nuno Taveira editores, Lidel, Edições Técnicas, Lisboa, Portugal. (ISBN - 978-972-757-576-3).
https://www.fca.pt/cgi-bin/lidel_main.cgi?op=3&mnu=100&edicao=1&isbn=978-989-752-057-0&novidade=0
http://issuu.com/lidel/docs/microbiologia_medica_volume_1?mode=embed&layout=http%3A%2F%2Fskin.issuu.com%2Fv%2Flight%2Flayout.xml&showFlipBtn=true
17. **Viveiros M**, Couto I, Rossetti ML, da Silva PA (2014) Otimização, validação e controlo de qualidade de testes moleculares de diagnóstico. In: Abordagens Moleculares em Veterinária. Mónica V. Cunha e João Inácio editores, Lidel, Edições Técnicas, Lisboa, Portugal. (ISBN - 978-989-752-034-1).
https://www.fca.pt/cgi-bin/lidel_main.cgi?op=3&mnu=100&edicao=1&isbn=978-989-752-034-1
<http://issuu.com/lidel/docs/abordagensmolecularesveterinaria/1>

18. Costa P, Couto I, **Viveiros M**, Inácio J. (2014) Nested and Multiplex Real Time PCR Using Dual-Labeled Probes: Detecting and Discriminating *Mycobacterium tuberculosis* Complex Members In Cultures And Animal Tissues. In: Veterinary Infection Biology: Molecular Diagnostics and High-Throughput Strategies (Methods in Molecular Biology Series). Monica Cunha and João Inácio Editors. Humana Press, Springer Science+Business Media, LLC. Londres, Reino Unido. Vol. 1247. (ISBN 978-1-4939-2003-7).
<http://www.springer.com/medicine/internal/book/978-1-4939-2003-7>
19. Rodrigues L, **Viveiros M**, Ainsa J. (2015) Measuring Efflux and Permeability in Mycobacteria. In: Mycobacteria Protocols (Methods in Molecular Biology Series), Tanya Parish and David Roberts, Editors. Humana Press, Springer Science+Business Media, LLC. Londres, Reino Unido. 3rd edition., XII, 412 p.Vol. 1285. (ISBN 978-1-4939-2449-3).
<http://www.springer.com/life+sciences/microbiology/book/978-1-4939-2449-3>
20. Armada A, Martins C, Spengler G, Molnar J, Amaral L, Rodrigues AS, **Viveiros M**. (2016) Fluorimetric Methods for Analysis of Permeability, Drug Transport Kinetics, and Inhibition of the ABCB1 Membrane Transporter. In: Cancer Drug Resistance: Overviews and Methods (Methods in Molecular Biology Series). José Rueff and Sebastião Rodrigues Editors. Humana Press, Springer Science+Business Media, LLC. Londres, Reino Unido. Vol. 1247. (ISBN 978-1-4939-3347-1 and 978-1-4939-3345-7).
<http://www.springer.com/us/book/9781493933457>
21. da Silva PEA, Machado, Ramos D, Couto I, Von Groll A, **Viveiros M**. (2016) Efflux Pumps in Mycobacteria: Antimicrobial Resistance, Physiological Functions, and Role in Pathogenicity. In: Efflux-Mediated Antimicrobial Resistance in Bacteria: Mechanisms, Regulation and Clinical Implications. Xian-Zhi Li, Christopher A. Elkins, Helen I. Zgurskaya Editors Springer International Publishing Switzerland pg. 527-559 (ISBN 978-3-319-39656-9 and 978-3-319-39658-3)
http://link.springer.com/chapter/10.1007/978-3-319-39658-3_21
22. Machado D, Lecorche E, Mougari F, Cambau E, **Viveiros M**. (2019) Insights on Mycobacterium leprae Efflux Pumps and Their Implications in Drug Resistance and Virulence. In: Evolution of Genetic Mechanisms of Antibiotic Resistance. Silvia Buroni, Simona Pollini, Gian Maria Rossolini and Elena Perrin Editors. Frontiers Microbiology Research Topic. 2019 13;9:3072. doi: 10.3389/fmicb.2018.03072. eCollection 2019. (ISSN 1664-8714 and ISBN 978-2-88963-222-0)
<https://www.frontiersin.org/research-topics/6601/evolution-of-genetic-mechanisms-of-antibiotic-resistance>
23. Costa SS, Sobkowiak B, Parreira R, Edgeworth JD, **Viveiros M**, Clark TG, Couto I. (2019) Genetic Diversity of norA, Coding for a Main Efflux Pump of Staphylococcus aureus. In: Evolution of Genetic Mechanisms of Antibiotic Resistance. Silvia Buroni, Simona Pollini, Gian Maria Rossolini and Elena Perrin Editors. Frontiers Microbiology Research Topic. 2019 9;9:710. doi: 10.3389/fmicb.2018.03072. eCollection 2019. (ISSN 1664-8714 and ISBN 978-2-88963-222-0)
<https://www.frontiersin.org/research-topics/6601/evolution-of-genetic-mechanisms-of-antibiotic-resistance>

PARTICIPATION AND COORDINATION OF RESEARCH PROJECTS:

As Coordinator (n=12):

1. 2004 - 2006 - Principal Investigator/Coordinator of the project - Fundação Calouste Gulbenkian - " Diagnóstico Rápido da Tuberculose Multiresistente na Grande Lisboa".
2. 2005 - 2007 - Principal Investigator/Coordinator - Fundação para a Ciência e Tecnologia - 1ST PHASE - (POCTI/SAU- MMO/59370/2004) "Bombas de Efluxo em *M. tuberculosis*: caracterização molecular dos mecanismos de efluxo e uso de inibidores de efluxo como novos compostos anti-bacilares - Efflux-pumps in *M. tuberculosis*: molecular characterization of the efflux mechanism and use of efflux inhibitors as new anti-TB drugs".
3. 2007 - 2009 - Principal Investigator/Coordinator - Fundação para a Ciência e Tecnologia - 2ND PHASE - (PPCDT/SAU- MMO/59370/2004) "Bombas de efluxo em *Mycobacterium tuberculosis*: caracterização molecular dos mecanismos de efluxo e uso de inibidores de efluxo como novos compostos anti-bacilares - Efflux-pumps in drug resistance of *Mycobacterium tuberculosis*: Molecular characterisation of the efflux mechanism and use of efflux inhibitors as new anti-tubercular compounds".
4. 2008-2012 - Principal Investigator/Coordinator - Fundação Calouste Gulbenkian - Projecto de apoio ao Plano Estratégico de Controlo da Tuberculose de Moçambique - Support for the Strategic Plan to Fight TB in Mozambique. Fundação Calouste Gulbenkian, Instituto de Higiene e Medicina Tropical, Instituto Nacional de Saúde Dr. Ricardo Jorge.
5. 2008 - 2011 - Principal Investigator/Coordinator - Fundação para a Ciência e Tecnologia - (PTDC/BIAMIC/ 71280/2006) - Dinâmica fisiológica e mutacional da resistência aos antibióticos em *Mycobacterium tuberculosis*: a emergência da Tuberculose Multi-Resistente. - Mutational and physiological dynamics of drug resistance in *Mycobacterium tuberculosis*: the emergence of Multi-Drug Resistant Tuberculosis.
6. 2009 - 2013 - Principal Investigator/Coordinator - Fundação para a Ciência e Tecnologia - (PTDC/SAUFCF/ 102807/2008) "Enhancing the killing of intracellular multi-drug resistant tuberculosis (MDRTB) by human macrophages: a new chemotherapeutic strategy to fight MDRTB".
7. 2009 - 2013 - Principal Investigator/Coordinator - Fundação para a Ciência e Tecnologia - (PTDC/BIAMIC/ 105509/2008) "Helper compounds against multidrug resistant bacteria: revealing their mechanism of action".
8. 2012 - 2015 - Principal Investigator/Coordinator (Component IHMT/UNL) - "Formação em Diagnóstico Laboratorial de Tuberculose - ForDILAB TB". Projecto conjunto Fundação Calouste Gulbenkian, Instituto de Higiene e Medicina Tropical e Instituto Nacional de Saúde Dr. Ricardo Jorge - Fundação Calouste Gulbenkian (instituição proponente – Dr^a Maria Herminia Cabral - Parceiros: Instituto de Higiene e Medicina Tropical (Prof. Doutor Paulo Ferrinho, Prof. Doutor Isabel Leitão Couto e Prof. Doutor João Piedade) e Instituto Nacional de Saúde Dr. Ricardo Jorge (Professor Doutor José Calheiros e Dr^o Maria João Simões). Submetido ao Secretariado Executivo da Comunidade dos Países de Língua Portuguesa, no âmbito do Plano Estratégico de Cooperação em Saúde da CPLP.
Nota: Projecto com o apoio e patrocínio do Representante Especial para Tuberculose do Secretário Geral das Nações Unidas, Sua Ex^a o Presidente da República Portuguesa, Dr. Jorge Sampaio.
9. 2014 - 2017 - Principal Investigator/Coordinator in Portugal (Component IHMT/UNL) - Jose R. Lapa e Silva/UFRJ Coordinator/PI Brazil - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) – Projecto "Ciências em Fronteiras/Professor Visitante Especial" - Chamada de Projetos Programa Pesquisador Visitante Especial (PVE) - 1º Cronograma de 2014 (Proc.nº 88881.064961/2014-01) - "Inovação em nível laboratorial no controle de Tuberculose nos Estados do Rio de Janeiro e Amazonas".

10. 2018-2020 - Principal Investigator/Coordinator – GILEAD - Programa Gilead GÉNESE, referência PGG/012/2017 - Aplicação de nanopartículas superparamagnéticas no diagnóstico rápido, simultâneo e não invasivo da infecção pelo VIH e da tuberculose. Co-PI: Doutora Diana Machado
11. 2018-2019 - Global Alliance for Tuberculosis Drug Development - TB Alliance Pretomanid_NCLN_Micro_002 Study - "Determination of the minimum inhibitory concentration of pretomanid against *M. tuberculosis* using the BACTEC MGIT 960 instrument -". PI: Miguel Viveiros | co-PI: Diana Machado.
12. 2018-2021 - Principal Investigator/Coordinator - Fundação para a Ciencia e Tecnologia – (PTDC/BIA-MIC/30692/2017) – "MtbEPis: Targeting efflux pumps in drug resistant *Mycobacterium tuberculosis*: an approach to prevent efflux-mediated resistance and boost therapy in active and latent tuberculosis". -. PI: Miguel Viveiros | co-PI: Diana Machado.

As Member of the Research Team (n=20):

1. 1992 - 1994 - Junior Researcher in the project - C.E.E./D.G.XII - "AIDS Clinical and Seroimmunological reevaluation of HIV-2 positive people of Guiné-Bissau"; (Contract N° TS2 - 001- P(TT) - EEC)- Coordinator - Prof. Wanda Canas-Ferreira.
2. 1994 - 1997 - Researcher in the project - Fundação Calouste Gulbenkian - (Desp-FCG-05/01/1994) - "Estudo cooperativo internacional sobre a imunidade protectora em tuberculose: investigações clinico-epidemiológicas e laboratoriais relacionadas com perspectivas de novos métodos de diagnóstico e pesquisa de nova geração de vacinas" - Coordinator - Prof. Hugo Ayres Lopes David.
3. 1995 - 1998 - Researcher in the project - Comissão Nacional de Luta Contra a SIDA - National Committee Against AIDS -(Projecto N° 9-1.10.6./94) -"Estudo da relação tuberculose-SIDA e dos problemas de transmissão da tuberculose nas populações de alto risco, com a introdução, desenvolvimento e aplicação prática de novos métodos de diagnóstico rápido da tuberculose". Coordinator - Prof. Hugo Ayres Lopes David.
4. 2002 - 2005 - Researcher in the project - Fundação Calouste Gulbenkian - (SDH.IC.I.01.17) - " Grupo de Trabalho para a Tuberculose na Grande Lisboa - TB-TASK-FORCE for Greater Lisbon" - Coordinator - Prof. Leonard Amaral.
5. 2002 - 2005 - Researcher in the project - Fundação Calouste Gulbenkian - " Pesquisa de novos marcadores de imunidade celular para a detecção precoce da infecção por *Mycobacterium tuberculosis* - New cellular immune markers for early detection of active TB" - Coordinator - Prof. Leonard Amaral.
6. 2002 - 2005 - Researcher in the project - Fundação para a Ciencia e Tecnologia - (POCTI/FCB/37579/2001)" A actividade antimicobacteriana dos derivados de fenotiazinas, uma alternativa efectiva contra *M. tuberculosis* resistente aos antibióticos - Phenothiazines as an effective alternative against MDRTB" - Coordinator - Prof. Leonard Amaral.
7. 2008 - 2011 - Member/Researcher in the EU Consortium/Action – “Cost Action BM0701 - Antibiotic Transport and Efflux : New Strategies to combat bacterial resistance (Acronym:ATENS) “- European Science Foundation.
8. 2009 - 2012 - Researcher in the project – “Diagnóstico e Epidemiologia Molecular de M/XDR-TB na Grande Lisboa: a Detecção Precoce na Prevenção da Emergência e Disseminação de Estirpes de *M. tuberculosis* Extensivamente Resistentes. - Early Molecular Detection of M/XDRTB in the Great Lisbon Healthcare Region” - Fundação Calouste Gulbenkian - Serviço de Saúde e Desenvolvimento Humano – Ref. P-99934 - Programa de Apoio à Investigação na Área da Microbiologia Clínica. Coordinator - Prof. Isabel Couto.

9. 2010 - 2013 - Researcher in the project - Quadro de Referência Estratégico Nacional (QREN)- "Acompanhamento da sequenciação e validação de "primers", anotação e sua validação, construção de uma "toolbox" de transcriptómica dirigida e implementação de ensaios de qRT-PCR de duas estirpes de *Sphingomonas* sp. produtoras de carotenoides". Coordinator - Biotech company - Biotrend, Lda.
10. 2010 - 2013 - Researcher in the project - Fundação para a Ciência e Tecnologia - (PTDC/CVT/111634/2009) – ZoonTB - Novas abordagens moleculares para a detecção e discriminação de membros do Complexo *Mycobacterium tuberculosis* associados a tuberculose animal e avaliação do potencial zoonótico destas espécies em Portugal” - Instituto Nacional de Recursos Biológicos, I.P. (INRB/MADRP) instituição proponente - Coordinator - Inv. Doutor João Inácio.
11. 2011 - 2014 - Researcher in the project - Fundação para a Ciência e Tecnologia - (PTDC/BIA-MIC/121859/2010) - “ Type-II NADH-menaquinone oxidoreductase (NDH-2) and the respiratory chain of *M. tuberculosis*: new therapeutic targets to fight tuberculosis.” - Grupo de Micobactérias da Unidade de Microbiologia do IHMT/UNL (instituição proponente). Parceiro: Fundação da Faculdade de Ciências e Tecnologia (FFCT/FCT/UNL). Coordinator - Prof. Isabel Couto.
12. 2013 - 2016 - Researcher in the project - Fundação para a Ciência e Tecnologia - (PTDC/IVC-COM/5016/2012) - “OSYRISH - Organizational and Informational System to Improve Healthcare Associated Infections management in a set of Hospitals -.” Unidade de Saúde Internacional do IHMT/UNL (instituição proponente). Parceiros: Hospitais de Lisboa e da CPLP. Coordinator - Prof. Luis Lapão.
13. 2015-2017 - Researcher in the project - Programa Iniciativas em Saúde Pública | EEA Grants - HAITool – A Toolkit to Prevent, Manage and Control Healthcare-Associated Infections in Portugal (EEA Grants 182DT3). Unidade de Saúde Internacional do IHMT/UNL (instituição proponente). Parceiros: Centro Hospitalar de Lisboa Oriental - Lisbon, Portugal e The University Hospital of Northern Norway, Tromsø, Norway. Coordinator - Prof. Luis Lapão.
14. 2015 - 2018 - Researcher in the project - Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro - “Infecção Mista com diferentes linhagens de *M. tuberculosis* ou *M. atípicas*: papel no diagnóstico e tratamento da TB e TB resistente”, Entidade financiadora FAPERJ – Edital FAPERJ N.º 03/2015 – “Apoio a Projetos Temáticos no Estado do Rio de Janeiro – 2015”. Esta proposta integra a estratégia de Gestão em áreas Estratégicas das Unidades Acadêmicas da área da Saúde da UFRJ. Coordenação do Prof Afranio Lineu Kritski, Prof titular da Faculdade de Medicina da UFRJ.
15. 2017 – 2020 - Researcher in the project - Becton-Dickinson, USA 2017 - “Avaliação do sistema automatizado BACTEC MGIT 960-TB eXiST como teste quantitativo de suscetibilidade aos antimicrobianos para *Mycobacterium tuberculosis*”. Coordenado pela pesquisadora Doutora Erica Chimara, Instituto Adolfo Lutz, São Paulo.
16. 2017 – 2020 -- Researcher in the project - “Implementação de um sistema semiautomatizado de detecção de resistência a drogas de primeira linha no Centro de Referência para tratamento de tuberculose resistente do Estado do Rio Grande do Sul e avaliação do impacto da implementação dessa tecnologia, bem como monitoramento da tuberculose resistente no Centro de Referência”, Submetido à CHAMADA FAPERGS/MS/CNPq/SESRS n. 03/2017 PROGRAMA PESQUISA PARA O SUS: GESTÃO COMPARTILHADA EM SAÚDE PPSUS – 2017. Coordenado pela pesquisadora Doutora Elis Regina Dalla Costa.
17. 2018-2021 - Researcher in the project - Fundação para a Ciência e Tecnologia – (02/SAICT/2017: C493201324-00089525) “Preventing antimicrobial resistance in the community - the safe use of biocides” Unidade de Microbiologia Médica e GHTM do IHMT/UNL (instituição proponente). Parceiro Faculdade de Medicina Veterinária da Universidade de Lisboa. Coordinator - Prof. Isabel Couto.

18. 2018-2021 - Researcher in the project - Fundação para a Ciência e Tecnologia – “BYDRUG: Immunotargeting efflux systems for therapeutic modulation of multidrug resistant bacteria.” Fundação para a Ciência e a Tecnologia - PTDC. PI: Ricardo Vieira-Pires | co-PI: Miguel Viveiros.
19. 2018-2021 - Researcher in the project - Fundação para a Ciência e Tecnologia – (PTDC/QUIQOR/32406/2017) “IonPharma4TB: Active pharmaceutical ionic liquids as new platform for effective treatment of tuberculosis (TB-ILs).” Fundação para a Ciência e a Tecnologia -. PI: Luís Branco | co-PI: Miguel Viveiros.
20. 2018-2021 - Researcher in the project - Fundação para a Ciência e Tecnologia – (PTDC/MEDQUI/29036/2017) - “TARGTUB - Targeting multi-resistant tuberculosis with new potent isoniazid derivatives: an integrated medicinal chemistry approach.” Fundação para a Ciência e a Tecnologia - PTDC/MEDQUI/29036/2017. PI: Filomena Leitão | co-PI: Miguel Machuqueiro. 2018-2021.

EXPERIENCE AS SCIENTIFIC ADVISER/SUPERVISOR (N=53):

Post-doctoral fellows supervised or ongoing (n= 3)

Post-doctoral fellows co-supervised or ongoing (n= 2)

PhD Students supervised or ongoing (n= 4)

PhD students co-supervised or ongoing (n= 5)

MSc Students supervised, co-supervised or ongoing (n = 33)

BSc students supervised (n = 6)

1. 1995/1996 – Co-supervisor of Paulo Jorge Gonçalves de Bettencourt - Licenciatura Thesis in Engenharia Biotecnológica do Instituto Superior de Humanidades e Tecnologias (ISHT) / Universidade Lusófona - Supervisor Prof^ª. Doutora Laura Brum
2. 1996/1997 - Supervisor of Patrícia Raquel Fernandes de Melo Moreira - Licenciatura Thesis in Microbiologia pela Escola Superior de Biotecnologia da Universidade Católica Portuguesa - "Avaliação do teste de diagnóstico *Mycobacterium tuberculosis* LCX Abbott para amostras extrapulmonares".
3. 1996/1997 - Supervisor of Susana Frazão Pinheiro - Licenciatura Thesis in Microbiologia pela Escola Superior de Biotecnologia da Universidade Católica Portuguesa - "Avaliação do teste de identificação MTB LCX Abbott para amostras pulmonares".
4. 2001/2002 - Supervisor of Ana Isabel Caldeira de Jesus - Licenciatura Thesis in Engenharia Biotecnológica da Universidade Lusófona - "Resistência à tetraciclina em *Escherichia coli* por mecanismos de extrusão";.
5. 2003/2004 - Supervisor of Mafalda Lopes Brito - Licenciatura Thesis in Engenharia Biotecnológica do Instituto Superior Técnico da Universidade Técnica de Lisboa - "Resistência aos antibióticos em *Staphylococcus aureus* e *Escherichia coli* por mecanismos de extrusão".
6. 2003/2004 - Supervisor of - Francisco Estrela de Soure Dores - Licenciatura Thesis in Biologia Microbiana da Faculdade de Ciências de Lisboa - "Isolamento, purificação e caracterização de uma fracção proteica do envelope celular de *Staphylococcus aureus* associada à adaptação a elevadas concentrações de brometo de etídio".
7. 2004/2005 - Supervisor of Maria João Lobo da Cruz Rocha Monteiro Caetano - MSc in Medical Microbiology Thesis (IHMT/UNL) - "Diagnóstico molecular de micobacterioses em pacientes co-infectados com o VIH. Importância clínica, laboratorial e epidemiológica (em colaboração com o Hospital Egas Moniz)".
<http://sd01.ihmt.unl.pt/docbweb/plinkres.asp?Base=GERAL&Form=BIBLIO&StartRec=0&RecPag=5&NewSearch=1&SearchTxt=%22AU%20CAETANO%2C%20Maria%20Jo%20E3o%22%20%2B%20%22AU%20CAETANO%2C%20Ma%20ria%20Jo%20E3o%24%22>
<http://memoria-africa.ua.pt/Catalog/ShowRecord.aspx?MFN=393851>
8. 2004/2005 - Supervisor of Liliana Isabel Dias Rodrigues- MSc in Medical Microbiology Thesis (IHMT/UNL) - "Diagnóstico precoce da tuberculose multiresistente na Grande Lisboa".
<http://memoria-africa.ua.pt/Catalog/ShowRecord.aspx?MFN=393780>
9. 2006/2007 - Supervisor of - Ana Laura Paixão - "Modelação do efluxo de Brometo de Etídio em *Escherichia coli*". MSc in Biological Engineering from Instituto Superior Técnico da Universidade Técnica de Lisboa .
10. 2006/2007 - Supervisor of Ana Daniela de Araújo Sampaio - MSc in Medical Microbiology Thesis (IHMT/UNL)- "A contribuição da resistência fenotípica na resistência aos tuberculostáticos no género *Mycobacterium*".
<http://www.itqb.unl.pt/events/master-thesis/master-thesis-in-medical-microbiology-7>

11. 2006/2007 - Supervisor of Ana Catarina Heitor Martins Cardoso - MSc in Medical Microbiology Thesis (IHMT/UNL)- "Efluxo de compostos fluorescentes em *Escherichia coli* e sua correlação com a resistência clínica aos antibióticos." <http://www.itqb.unl.pt/events/master-thesis/master-thesis-in-medical-microbiology-4>
12. 2006/2007 - Co-supervisor of Sofia Maria Mourão Marques dos Santos Costa – MSc in Medical Microbiology Thesis (IHMT/UNL) - "Caracterização de proteínas do envelope celular de *S. aureus* associadas ao efluxo de compostos biocidas". <https://run.unl.pt/handle/10362/19283>
<http://www.itqb.unl.pt/support-services/library/itqb-thesis>
13. 2007/2008 - Supervisor of Nadia Borges Charepe - MSc in Biomedical Sciences Thesis (IHMT/UNL) - "Estudo biológico dos mecanismos de resistência aos antibióticos desenvolvido em *Escherichia coli* sujeita a pressão antibiótica prolongada". <https://run.unl.pt/handle/10362/19222>
<http://memoria-africa.ua.pt/Catalog/ShowRecord.aspx?MFN=393970>
14. 2008/2009 - Supervisor of Jorge Alexandre dos Santos Ramos – MSc in Medical Microbiology Thesis (IHMT/UNL) - "Avaliação do efeito sinérgico de inibidores de bombas efluxo na susceptibilidade do género *Mycobacterium* aos tuberculostáticos". <https://run.unl.pt/bitstream/10362/10272/1/Transporte%20de%20brometo%20de%20et%20C3%ADdio%20atrav%20C3%A9s%20da%20parede%20de%20Mycobacterium%20smegmatis.pdf>
15. 2008/2009 - Supervisor of Susana Cristina Nunes Costa – MSc in Medical Microbiology Thesis (IHMT/UNL) - "Caracterização bioquímica e molecular do efluxo de Brometo de Etídeo em *Escherichia coli*" <https://run.unl.pt/handle/10362/5350>
16. 2004/2008 - Co-supervisor of Marta Lopes Martins (SFRH/BD/14319/2003) - PhD Thesis in Medical Microbiology of IHMT/Universidade Nova de Lisboa - "The antimycobacterial activity of thioridazine derivatives, against Drug Resistant *Mycobacterium tuberculosis*. In vitro, ex vivo and in vivo studies".- Supervisor Prof. Doutor Leonard Amaral. <http://sd01.ihmt.unl.pt/docbweb/plinkres.asp?Base=GERAL&Form=BIBLIO&StartRec=0&RecPag=5&NewSearch=1&SearchTxt=%22AU%20MARTINS%2C%20Marta%20Lopes%22%20%2B%20%22AU%20MARTINS%2C%20Marta%20Lopes%24%22>
<http://memoria-africa.ua.pt/Catalog/ShowRecord.aspx?MFN=393922>
17. 2004/2008 - Co-supervisor of Ana Sofia Fernandes Martins (SFRH/BD/19445/2004)– - PhD Thesis in Medical Microbiology of IHMT/Universidade Nova de Lisboa -"The effects of *Carpobrotus edulis* methanol extract and purified compound(s) against multi-drug resistant *Mycobacterium tuberculosis* strains" - Supervisor Prof. Doutor Leonard Amaral.
18. 2008/2009 – Co-supervisor of Diana Isabel Oliveira Machado– MSc in Medical Microbiology Thesis (IHMT/UNL) "Dinâmica fisiológica e mutacional da multirresistência em *Mycobacterium tuberculosis*." Supervisor Prof. Doutor Isabel Couto.
19. 2006/2010 - Supervisor of Liliana Isabel Dias Rodrigues (SFRH/BD/24931/2005) - PhD Thesis in Medical Microbiology of IHMT/Universidade Nova de Lisboa - "The role of the efflux mechanisms in Multi-drug Resistance in *Mycobacterium tuberculosis*". <https://run.unl.pt/handle/10362/4813>

20. 2009/2014 - Supervisor of Diana Isabel Oliveira Machado (SFRH/BD/65060/2009) - PhD Thesis in Medical Microbiology of IHMT/Universidade Nova de Lisboa - "The dynamics of drug resistance in *Mycobacterium tuberculosis*: exploring the biological basis of multi- and extensively drug resistant tuberculosis (MDR/XDRTB) as a route for alternative therapeutic strategies".
<https://run.unl.pt/handle/10362/20311>
21. 2009/2014 - Co-supervisor of Pedro Miguel Nisa Costa (SFRH/BD/64136/2009) - PhD Thesis in Medical Microbiology of IHMT/Universidade Nova de Lisboa - "Novas abordagens moleculares para a detecção e diferenciação rápida de espécies do complexo *Mycobacterium tuberculosis* e avaliação do seu potencial zoonótico em Portugal". - Supervisor Doutor João Inácio.
<https://run.unl.pt/handle/10362/19272>
22. 2009/2010 – Co-supervisor of Miguel José Simas do Rosário Evaristo – MSc in Biomedical Sciences Thesis (IHMT/UNL) - "Biological activity of well-defined heterocyclic compounds on efflux pump systems of bacteria and cancer cells". - Supervisor Doutora Gabriella Spengler.
<https://run.unl.pt/handle/10362/5617>
23. 2010/2014 - Post-Doc Supervisor of Marta Sofia Lopes Martins (SFRH/BPD/63871/2009) - Post-Doc program in Medical Microbiology of IHMT/Universidade Nova de Lisboa - "Targeting the human macrophage with combinations of second-line TB drugs and inhibitors of Ca²⁺ and K⁺ transport to enhance the killing of intracellular Multi-Drug Resistant *M. tuberculosis* (MDR-TB) – a novel approach to limit the emergence of XDRTB".
24. 2010/2011 - Co-supervisor of Lisa Santos Machado – MSc in Medical Microbiology Thesis (IHMT/UNL) - "The inhibitory activity of synthetic compounds and ions against transporters of multi-drug resistant bacteria". - Supervisor Professor Doutor Leonard Amaral.
<https://run.unl.pt/handle/10362/7712>
25. 2010/2011 - Supervisor of Antónia Rosa Trindade Pinto – MSc in Biomedical Sciences Thesis (IHMT/UNL) - Resistência mediada por efluxo em *Escherichia coli*: desenvolvimento de novas estratégias terapêuticas."
<https://run.unl.pt/handle/10362/14014>
26. 2010/2011 - Co-supervisor of Vanessa Roque Cabral – MSc in Química Farmacêutica e Terapêutica da Faculdade de Farmácia da Universidade de Lisboa - "Efflux pump inhibitors in multidrug resistant bacterial strains from medicinal plants". Supervisor - Professora Doutora Maria José Umbelino Ferreira.
<http://repositorio.ul.pt/handle/10451/11231>
27. 2010/2011 – Co-supervisor of Ana Carolina Vencá – MSc in Biotecnologia do Instituto Superior Técnico da Universidade Técnica de Lisboa, "Identification and characterisation of efflux pumps in *Rhodococcus erythropolis*." Supervisor - Doutora Carla C.C.R. de Carvalho.
<https://fenix.tecnico.ulisboa.pt/cursos/mbiotec/dissertacao/2353642392242>
28. 2011/2013 - Co-supervisor of Nureisha Abdul Gafur Cadir – MSc in Saúde Pública da Faculdade de Medicina da Universidade Eduardo Mondlane – Mozambique - "Avaliação do desempenho dos testes imunocromatográficos rápidos (BD MGIT Tbc Identification Test e TB Ag MPT64 Device) para a diferenciação do Complexo *M. tuberculosis* das Micobactérias Não Tuberculosas". Supervisores - Professor Doutor Mohsin Sidat e Doutor Eduardo Samo Gudo.
29. 2012/2015 - Post-Doc Supervisor of Paulo Rabna (SFRH/BPD 64/2011) Instituto Nacional de Saúde Pública da Guiné-Bissau - "Tuberculose Multirresistente na Guiné-Bissau".

30. 2012/2013 – Supervisor of Vânia Filipa Ferreira da Silva – MSc in Biomedical Sciences Thesis (IHMT/UNL) – “Contribuição dos sistemas de efluxo na resistência à claritromicina no complexo *Mycobacterium avium*.” Co-supervisor – Professor Isabel Couto.
31. 2013/2014 – Co-supervisor of Ana Luísa Chocalheiro – MSc in Biotecnologia da Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa, “Application of Lab-on-Paper technology to colorimetric biosensors for the detection of tuberculous mycobacteria.” Supervisor – Professor Doutora Elvira Fortunato.
<https://run.unl.pt/handle/10362/13836>
32. 2013/2014 – Co-supervisor of André Meneses Valério – MSc in Engenharia Biomédica da Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa, “Desenvolvimento de testes de susceptibilidade a antibióticos do tipo E-tests em suportes de papel utilizando a tecnologia lab-on-paper” Supervisor – Professor Doutora Elvira Fortunato.
<http://www.fct.unl.pt/en/node/26736>
33. 2013/2017 - Supervisor of Moisés Francisco - PhD Thesis in Medical Microbiology of IHMT/Universidade Nova de Lisboa - “Caracterização microbiológica e molecular das estirpes de Salmonella spp isoladas em amostras de fezes, águas residuais e em ovos de produção aviárias na região de Luanda e dos seus perfis de resistência aos antimicrobianos – o seu impacto na saúde pública.”. Co-supervisor – Professor Constança Pomba
34. 2015/2018 - Supervisor of Ana Maria Buttle de Mendonça Mourão Possidónio de Armada - PhD Thesis in Human Genetics and Infectious Diseases of IHMT/Universidade Nova de Lisboa - “Modulation of ABC transporters in multidrug resistance (MDR): From prokaryotic to eukaryotic cells.” Co-supervisor – Professor Sebastião Rodrigues.
35. 2014/2017 - Post-Doc Co-Supervisor of – João Ruben Lucas Mota Perdigão (SFRH/BPD/95406/2013) - Post-Doc program in Microbiology of Pharmacy Faculty/Universidade de Lisboa - “Tuberculosis in Portugal and Portuguese-speaking African Countries: From Genomics to Product Development”. Supervisor – Professora Doutora Isabel Portugal.
36. 2014/2015 - Supervisor of Ana Sofia Mourão Simões – MSc in Medical Microbiology Thesis (IHMT/UNL) - “Contribuição do efluxo para a aquisição de resistência aos antibióticos em isolados clínicos de *Acinetobacter baumannii* . Co-supervisor Doutora Diana Machado.
<https://run.unl.pt/handle/10362/19196>
37. 2014/2015 – Supervisor of Marta Isabel Martins Gabriel – MSc in Biomedical Sciences Thesis (IHMT/UNL) – “Resposta imunitária inflamatória de macrófagos na presença de inibidores de efluxo.” Co-supervisors – Professora Gabriela Santos-Gomes e Investigadora Ana Maria Buttle de Mendonça Mourão Possidónio de Armada.
<https://run.unl.pt/handle/10362/19084>
38. 2014/2015 – Co-Supervisor in Portugal of – Tatiane Silveira Coelho - Bolsa Doutorado Sandwich no Brasil – PhD thesis - “Relação entre o mecanismo de efluxo e a resistência aos antimicrobianos em isolados clínicos de *Mycobacterium tuberculosis*” -.Coorientador em Portugal: Prof^a. Dr. Miguel Viveiros. Orientador no Brasil: Prof. Dr. Pedro Eduardo Almeida da Silva e Prof. Dra. Andrea von Groll (NUPEMM/FURG).
<http://www.lume.ufrgs.br/handle/10183/117897>
39. 2015/2018 - Post-Doc Supervisor of Diana Isabel Oliveira Machado (SFRH/BPD/100688/2014) - Post-Doc program in Medical Microbiology of IHMT/Universidade Nova de Lisboa - “Exploring the mode of action of efflux inhibitors against *Mycobacterium tuberculosis*: an approach to prevent efflux-mediated resistance and boost therapy in active and latent tuberculosis”.

40. 2015/2018 – Co-Supervisor of Ana Maria Pinho Tavares (PD/BD/105916/2014) – PhD Thesis in Global Public Health of IHMT/Universidade Nova de Lisboa in association with Universidade do Porto (FCT Doctoral Program in Global Public Health)- “HIV, tuberculosis and coinfection among migrant populations living in Portugal”. Supervisor: Professor Sónia Dias (ENSP/UNL)
41. 2015/2016 - Post-Doc Co-Supervisor of Alexandra Simões - Post-Doc program in Medical Microbiology of IHMT/Universidade Nova de Lisboa - “Using molecular, epidemiological, clinical and social data to prevent and control antibiotic resistant healthcare-associated infections”. Programa Iniciativas em Saúde Pública | EEA Grants - HAITool – A Toolkit to Prevent, Manage and Control Healthcare-Associated Infections in Portugal (EEA Grants 182DT3). Unidade de Saúde Internacional do IHMT/UNL (instituição proponente). Parceiros: Centro Hospitalar de Lisboa Oriental - Lisbon, Portugal e The University Hospital of Northern Norway, Tromsø, Norway. Main-supervisor and Coordinator – Investigador Doutor Luis Lapão.
42. 2016/2017 - Supervisor of Mariana Silva – MSc in Medical Microbiology Thesis (UNL) – “A contribuição do efluxo na resistência aos β -lactâmicos em isolados clínicos de *Escherichia coli*”. Co-supervisor – Doutora Diana Machado
43. 2016/2017 - Supervisor of Jessica Antunes – MSc in Medical Microbiology Thesis (UNL) – “Estudo da contribuição de bombas de efluxo, porinas e β -lactamases na resistência aos carbapenemos em isolados clínicos de *Acinetobacter baumannii*.” Co-supervisor – Doutora Diana Machado
44. 2016/2017 – Supervisor of Ana Raquel Esteves Costa– MSc in Biomedical Sciences Thesis (IHMT/UNL) – “Contribuição do efluxo para a emergência da resistência em bactérias persistentes.” Co-supervisor – Doutora Diana Machado
45. 2016/2017 – Supervisor of Samuel Antunes – MSc in Biomedical Sciences Thesis (IHMT/UNL) – “Aplicação de um método fluorométrico em placa de 96 poços para a detecção de actividade de efluxo em bactérias”. Co-supervisor – Doutora Diana Machado
46. 2017/2018 – Co-supervisor of Maria João Theron - MSc Thesis in Biomedical Sciences (IHMT/UNL) – “Caracterização da actividade de efluxo de Hoechst 33258 em *Escherichia coli*.” Supervisor: Diana Machado.
47. 2017/2018 – Co-supervisor of Fátima Rodrigues - MSc Thesis in Biomedical Sciences (IHMT/UNL) – “Caracterização dos mecanismos de resistência à colistina em isolados clínicos de *Acinetobacter baumannii* resistentes aos carbapenemos.” Supervisor: Diana Machado | co-supervisor: Miguel Viveiros.
48. 2018/2019 – Supervisor of José Ribeiro – MSc Thesis in Medical Microbiology (UNL) – “Uma abordagem bioinformática para o estudo da contribuição das bombas de efluxo “Small Multidrug Resistance” na resistência aos antibióticos em *Acinetobacter baumannii* através de análise de genoma completo” - co-supervisor: Diana Machado. Ongoing.
49. 2018/2019 – Co-supervisor of Iolanda Neves – MSc Thesis in Medical Microbiology (UNL) – “O papel dos mutantes *hip* na resistência aos antibióticos mediada por efluxo em bactérias persistentes” - Supervisor: Diana Machado | co-supervisor: Miguel Viveiros. Ongoing.
50. 2019/2020 – Co-supervisor of Debora Serra – MSc Thesis in Medical Microbiology (UNL) - Detecção e inibição da actividade de β -lactamases em isolados clínicos de *Escherichia coli* combinando inibidores de β -lactamases e inibidores de efluxo usando o método MTT: validação fenotípica e genotípica. Supervisor: Diana Machado | co-supervisor: Miguel Viveiros.
51. 2020/2022 – Co-supervisor of Inês Maia – MSc Thesis in Biomedical Sciences (IHMT/UNL) – “Estudo de competição entre substratos de bombas de efluxo em isolados clínicos de *Escherichia coli* por fluorimetria em tempo real usando Vermelho do Nilo”. Supervisor: Diana Machado | co-supervisor: Miguel Viveiros.

52. 2021/2022 – Co-supervisor of Bruna Pereira – MSc Thesis in Medical Microbiology (UNL) – “Pathogenesis of urinary infections by *Escherichia coli*: phenotypic and molecular characterization of virulence mechanisms”. Supervisor: Diana Machado | co-supervisor: Miguel Viveiros. Ongoing.
53. 2021/2022 – Co-supervisor of Sarah Göthe – MSc Thesis in Medical Microbiology (UNL) – “The contribution of oxidative stress to persisters formation and survival”. Supervisor: Diana Machado | co-supervisor: Miguel Viveiros. Ongoing.
54. 2021/2022 – Co-supervisor of Isabel Roseiro – MSc Thesis in Medical Microbiology (UNL) – “Characterization of the genetic diversity and virulence factors of *Mycobacterium avium* clinical strains”. Supervisor: Diana Machado | co-supervisor: Miguel Viveiros. Ongoing.

AWARDS:

2003 – Merit Award for Research in Infectious Diseases (2° Place) - Glaxo-Smithkline Fundation – Portuguese Society of Infectious Diseases - “A Implementação do Programa “TB-FAST-TRACK” de Combate à Tuberculose Multiresistente na Grande Lisboa - Implementatantion of the TB-FAST-TRACK program in Lisboa”.

2009 – Merit Award for Best Panel Communication National Congress of Microbiology and Biotechnology - Congresso Nacional de Microbiologia e Biotecnologia de 2009 - “Cell and Tissue Engineering, Biomaterials and Nanobiotechnologies”. Authors: Veigas B., Perdigão J., Portugal I., Couto I., Viveiros M. and Baptista P.V. (2009) Use of Au-nanoprobes for the detection of SNPs associated with antibiotic resistance in *Mycobacterium tuberculosis*. Congresso Microbiotec 2009. Congresso Nacional de Microbiologia e Biotecnologia MicroBiotec09. Vilamoura (Portugal) 28 a 30 de November de 2009.

2012 – Santander/Totta – Universidade Nova de Lisboa - Merit Award 2012 - Prémio de Mérito Científico Santander Totta – Universidade Nova de Lisboa – Title: NanoTB - Nanodiagnostics for XDRTB at point-of-need. Miguel Viveiros (IHMT/UNL), Pedro Baptista (FCT/UNL), Isabel Couto (IHMT/UNL).

2017 - Seal of Excellence European Union - European Commission, Horizon 2020, EU Framework Programme for Research and Innovation 2014-2020 - Seal of Excellence awarded to The project proposal 750982, HEMIC - Unravelling the healthy microbiome against respiratory infections: a crucial step for the development of novel preventive measures to address childhood mortality. Submitted under the Horizon 2020's Marie Skłodowska-Curie actions call H2020-MSCA-IF-2016 by Miguel LANASPA and INSTITUTO DE HIGIENE E MEDICINA TROPICAL. Supervisor Miguel Viveiros.

<https://ec.europa.eu/research/soe/index.cfm?pg=what>

2017 - Best Panel Communication on the Section “Health Microbiology and Biotechnology”. Authors: Jéssica Antunes, Diana Machado, Isabel Couto, Teresa Pacheco, Judite Batista, Cristina Toscano, and Miguel Viveiros. 2017. “Correlation between carbapenem resistance, β -lactamases, porins and efflux pumps in *Acinetobacter baumannii* clinical isolates.” Congresso Nacional de Microbiologia e Biotecnologia (MicroBiotec17). Porto, Portugal, 7-9 December 2017.

2018 – GILEAD AWARD - Programa Gilead GÉNESE, referência PGG/012/2017 - Aplicação de nanopartículas superparamagnéticas no diagnóstico rápido, simultâneo e não invasivo da infecção pelo VIH e da tuberculose. with Doutora Diana Machado and Doutor João Piedade.

2020 - PFIZER AWARD - Best Poster Communication at the III International Conference NOVAhealth Chronic Disease and Infection: Infection, Cancer and Global Health. Lisboa, Portugal. 9 October 2020 (Online conference). Authors: Diana Machado, Marco Pieroni, Miguel Viveiros. 2020. Targeting Mycobacterium tuberculosis membrane energetics with lipophilic efflux inhibitors as adjuvants of tuberculosis treatment.

SELECTED INVITED LECTURES (N=25):

1. **Viveiros M.** (2009). Evaluation of efflux pumps of Mycobacteria by a semi-automated EB method. Invited Speaker at COST Action BM0701: Antibiotic Transport and Efflux: New Strategies to combat bacterial resistance (ATENS), Cracovia (Polonia), 18 may 2009.
2. **Viveiros M.** (2010). Cutaneous infections caused by mycobacteria. Invited Speaker at the Spring Meeting of the Portuguese Society of Dermatology and Venereal Diseases. V. N. Gaia (Portugal), 23 - 24 April 2010.
3. **Viveiros M.** (2011). Atypical Mycobacteriosis - Infecções por micobacterias atípicas Invited Speaker at the XII Jornadas Nacionais de Infecçologia Pediátrica. Braga (Portugal), 19 - 21 de May 2011.
4. **Viveiros M.** (2011). Direct detection of resistance in *Mycobacterium tuberculosis*: from line to nano-probe assays. Invited Speaker at the World TB Day Conference - Contribution of scientific research in the fight against tuberculosis. Institute of Tropical Medicine, Antwerpia, (Belgica), a 22 de Março de 2011.
5. **Viveiros M.** (2011). Resistencia fisiológica em *Mycobacterium tuberculosis*: impacto na resistência adquirida e novas estratégias quimioterapeuticas adjuvantes Invited Speaker at the Simpósio Internacional de Tuberculose Avanços e desafios no século XXI 02 e 03 de Dezembro de 2011.
6. **Viveiros M.** (2012). Cost-efficient diagnosis of tuberculosis: culture, molecular techniques and immunological markers. Invited Speaker at the European Congress of Clinical Microbiology and Infectious. 22nd European Congress of Clinical Microbiology and Infectious Diseases, London, United Kingdom, 31 March – 3 April 2012.
7. **Viveiros M.** (2012). Test de susceptibilidad cuantitativo de 1^a y 2^a línea para *Mycobacterium tuberculosis* usando lo BACTEC MGIT 960 con software TB eXiST : un protocolo en desarrollo en Europa. Invited Speaker at the XVI Reunion del grupo español de Micobacteriologia - GEM 2012. Cordoba 22 – 24 March 2012
8. **Viveiros M.** (2012). The semi-quantitative drug susceptibility test of 1st and 2nd line drugs for *Mycobacterium tuberculosis* using the MGIT 960TBTM culture system coupled with the BD EpiCenter™ TB-eXiST software. XIV Simpósio Brasileiro de Micobactérias - XXI Congresso Latinoamericano de Microbiología. Santos, São Paulo, Brasil. 1-5 November 2012.
9. **Viveiros M.** (2013). Significance of Efflux in Multidrug resistance in *Mycobacterium tuberculosis*. Invited Speaker at the Gordon Research Conferences. Multi-Drug Efflux Systems. Shared Molecular Mechanisms but Diverging Roles in Physiology and Medicine. Four Points Sheraton / Holiday Inn Express, Ventura, (CA, USA), March 17-22.
10. **Viveiros M.** (2013). Epidemiology of infections due to NTM. Speaker at the Infections due to non-tuberculous mycobacteria: Educational Workshop – 23rd European Congress of Clinical Microbiology and Infectious (ECCMID). European Congress of Clinical Microbiology and Infectious Diseases, Berlin (Germany), 31 March to 3 April 2013.
11. **Viveiros M.** (2013) O Projecto FORDILAB-TB Formação em Diagnóstico Laboratorial de Tuberculose no espaço da CPLP. Seminar: Innovations for Tuberculosis Control, Maputo (Mozambique) 14 – 16 May 2013.
12. **Viveiros M.** (2013) "Estética y MNT. Un problema emergente en Portugal". XVII Taller Internacional sobre Tuberculosis, Barcelona (Spain) 4 – 5 November 2013.
13. **Viveiros M.** (2014) Efflux inhibitors as adjuvants in drug resistant tuberculosis therapy. World's Tuberculosis day international conference, Ghent University "Het Pand", Gent, Belgium. 21st March 2014.

14. **Viveiros M.** (2014). How to diagnose mycobacterial infections in low-income countries: Educational Workshop – Invited Speaker at the 24th European Congress of Clinical Microbiology and Infectious (ECCMID). European Congress of Clinical Microbiology and Infectious Diseases, Barcelona (Spain), 10th May 2014.
15. **Viveiros M.** (2014) Efflux inhibitors against drug resistant *Mycobacterium tuberculosis*: adjuvants of antimycobacterial agents and enhancers of macrophage killing activity. Invited Speaker at the VII Meeting of the Latin-American Society of Tuberculosis and other Micobacteriosis (SLAMTB), Canela, Brazil. 15th September 2014.
16. **Viveiros M.** (2014) Programatic Implementation of Molecular Tests for TB diagnoses in low and middle income countries – Challenges and Perspectives. Invited Speaker at the IV National Workshop of Brazilian Tuberculosis Research Network (REDETB), Canela, Brazil. 15th September 2014.
17. **Viveiros M.** (2014) Infecções respiratórias: tuberculose pulmonar - novos métodos de identificação e detecção de resistências - I Jornadas do Médico Interno de Patologia Clínica. Ordem dos Médicos, Lisboa, Portugal, 26th September 2014.
18. **Viveiros M.** (2015) Efflux Modulators as Adjuvants of Anti-Tuberculosis Therapy and Enhancers of Macrophage Killing Activity: A New Concerted Strategy Against Drug Resistant *Mycobacterium tuberculosis*. Invited Speaker at the Gordon Research Conferences. Multi-Drug Efflux Systems: A Paradigm Shift from Fundamental Mechanisms to Practical Applications. Renaissance Tuscany Il Ciocco Resort; Lucca (Barga), Italy, April 26th-May 1st.
19. **Viveiros M.** (2016). How to diagnose mycobacterial infections in low-income countries: Educational Workshop – Invited Speaker at the 24th European Congress of Clinical Microbiology and Infectious (ECCMID). European Congress of Clinical Microbiology and Infectious Diseases, Barcelona (Spain), 10th May 2014.
20. **Viveiros M.** (2016) Molecular Techniques will substitute Phenotypic Traditional approaches for MDR/XDR TB diagnosis? Invited Speaker at the V National Workshop of Brazilian Tuberculosis Research Network (REDETB), Maceió (Brazil). 22nd August 2016.
21. **Viveiros M.** (2017) Omics and Meta Systemic Approaches - Invited Speaker and Session moderator at the Gordon Research Conferences. Integrated Approaches to Understanding the Role of Multi-Drug Efflux Systems in Health and Disease. Hotel Galvez, Galveston, TX ,USA, March 26-31, 2017.
22. **Viveiros M.** (2018) Antimicrobial resistance: new mutations of *Mycobacterium leprae*. Invited Speaker and Session moderator at the Innovative tools and approaches to end the transmission of Mycobacterium session of the 15^o Congresso Brasileiro de Hansenologia. 13 a 17 de Novembro de 2018, Palmas – Tocantins (Brasil)
23. **Viveiros M.** (2019) “Anti-Microbial Resistance (AMR) in Tuberculosis and Non-Tuberculosis Mycobacteria: a slow selective process in progress in One-Health, One-World” Invited Speaker at the ICOHAR 2019 - ICOHAR International Conference on One Health Antimicrobial Resistance, Utrecht, (Netherlands) 16-18 April 2019
24. **Viveiros M.** (2019) “Multidrug resistance in tuberculosis and nontuberculous mycobacteria: a slow selective process in progress in One-Health/One-World”. Plenary Key-Note speaker at ASM South Australia 2019 – the Annual Scientific Meeting & Exhibition organised by the Australian Society for Microbiology. ASM South Australia 2019: Adelaide (Australia). 30 June - 3 July 2019.
25. **Viveiros M.** (2019) “*Mycobacterium tuberculosis* strains and their influence in the clinical evolution and response to therapy: Therapeutic constraints”., Speaker at the 35^o Congresso Nacional de Pneumologia 2019 – the Annual Scientific Meeting & Exhibition organised by the Portuguese Society for Pneumology. 35^o SPP Congress 2019 Albufeira (Algarve). 7 November- 9 November 2019.

CONFERENCE ORAL AND POSTER COMMUNICATIONS (N >250).

A selection of the most relevant oral and poster communications in international conferences can be found in the NOVA Research Portal link :

<https://novaresearch.unl.pt/en/persons/miguel-viveiros-bettencourt/publications/>